{"gene":"TNFSF11","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1997,"finding":"TRANCE (RANKL/TNFSF11) was cloned as a type II membrane protein of 316 amino acids expressed on activated T cells; its ectodomain activated c-Jun N-terminal kinase (JNK) in T cells upon interaction with its receptor, and its expression was controlled by calcineurin-regulated transcription factors downstream of TCR stimulation.","method":"Somatic cell genetic cloning, recombinant protein production, JNK kinase assay, Northern blot, chromosomal mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — original cloning paper with direct biochemical assays (JNK activation), replicated across multiple labs","pmids":["9312132"],"is_preprint":false},{"year":1997,"finding":"RANKL (TRANCE) was identified as the ligand for the receptor RANK on dendritic cells; RANKL augments dendritic cell ability to stimulate naive T-cell proliferation and increases survival of RANK+ T cells, establishing RANKL-RANK as a regulator of T cell–dendritic cell interactions.","method":"Direct expression cloning, mixed lymphocyte reaction, cell survival assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — original discovery paper with functional assays, highly cited and replicated","pmids":["9367155"],"is_preprint":false},{"year":1997,"finding":"TRANCE (RANKL) acts as a dendritic cell-specific survival factor by signaling through TRANCE-R (RANK) in a TRAF2-dependent manner, upregulating Bcl-xL expression to inhibit apoptosis of bone marrow-derived and monocyte-derived dendritic cells.","method":"In vitro DC survival assay, dominant-negative TRAF2 transgenic mice, Bcl-xL Western blot","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic (transgenic) and biochemical evidence, highly cited","pmids":["9396779"],"is_preprint":false},{"year":1998,"finding":"RANKL (ODF/OPGL) was identified as the osteoblast/stromal cell membrane-bound ligand for OPG/OCIF, functioning as the osteoclast differentiation factor (ODF). Soluble ectodomain of ODF induced osteoclast-like cell formation from spleen cells in the absence of osteoblasts/stromal cells, and this was blocked by OPG. RANKL expression in osteoblasts/stromal cells was upregulated by bone-resorbing factors.","method":"Expression cloning from stromal cell cDNA library, in vitro osteoclastogenesis assay, OPG blocking experiment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — foundational cloning and reconstitution experiment, independently replicated, >3000 citations","pmids":["9520411"],"is_preprint":false},{"year":1998,"finding":"RANKL (OPGL) is a TNF-related cytokine that replaces the requirement for stromal cells, vitamin D3, and glucocorticoids in osteoclastogenesis. It binds to a hematopoietic progenitor committed to the osteoclast lineage, stimulates rapid induction of osteoclast-specific genes, directly activates isolated mature osteoclasts in vitro, and causes systemic hypercalcemia when administered to mice in vivo. Its effects are blocked by OPG in vitro and in vivo.","method":"Recombinant protein production, in vitro osteoclastogenesis, gene expression analysis, in vivo mouse injection, OPG neutralization","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in vitro and in vivo validation, >4000 citations","pmids":["9568710"],"is_preprint":false},{"year":1999,"finding":"RANKL (OPGL) directly binds to and activates mature osteoclasts via RANK, inducing actin ring formation within 30 minutes—a cytoskeletal rearrangement required for bone resorption—and increases total bone surface erosion approximately 7-fold. Anti-RANK antibodies also induce actin ring formation, confirming RANK as the mediating receptor. OPG blocks these effects.","method":"Primary rat osteoclast culture on bone slices, scanning electron microscopy, actin ring immunofluorescence, antibody blocking","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — direct mechanistic experiment on mature osteoclasts with multiple orthogonal readouts","pmids":["10225954"],"is_preprint":false},{"year":1999,"finding":"RANKL-deficient (opgl-null) mice completely lack osteoclasts due to inability of osteoblasts to support osteoclastogenesis, show severe osteopetrosis, defective tooth eruption, defects in early T and B lymphocyte differentiation, and absence of all lymph nodes. This genetic evidence establishes RANKL as an essential osteoclast differentiation factor in vivo and a regulator of lymph node organogenesis.","method":"Gene knockout in mice, skeletal and immunological phenotyping, histology","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — definitive in vivo loss-of-function, multiple phenotypes, >2600 citations","pmids":["9950424"],"is_preprint":false},{"year":1999,"finding":"Activated T cells directly trigger osteoclastogenesis through RANKL expression; systemic T cell activation in vivo causes RANKL-mediated increases in osteoclastogenesis and bone loss. In a rat adjuvant arthritis model, OPG treatment blocking RANKL prevents bone and cartilage destruction but not inflammation, establishing that T-cell-derived RANKL drives pathological bone resorption.","method":"T cell activation in vivo, OPG treatment in rat adjuvant arthritis model, histology, bone density measurement","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic and pharmacological epistasis, >1400 citations","pmids":["10580503"],"is_preprint":false},{"year":1999,"finding":"TRANCE (RANKL) activates the antiapoptotic kinase Akt/PKB in osteoclasts through a signaling complex at TRANCE-R (RANK) that involves TRAF6 and c-Src. c-Src deficiency or Src-family kinase inhibitors block TRANCE-mediated PKB activation. TRAF6 and c-Src interact with each other and with TRANCE-R upon receptor engagement; TRAF6 enhances c-Src kinase activity, leading to tyrosine phosphorylation of c-Cbl.","method":"Co-immunoprecipitation, kinase assays, c-Src-deficient cells, pharmacological Src inhibitors","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical reconstitution of signaling complex, genetic validation, >500 citations","pmids":["10635328"],"is_preprint":false},{"year":1999,"finding":"TRANCE (RANKL) is shed from the plasma membrane as a soluble form by a metalloprotease activity consistent with TACE (TNF-alpha converting enzyme) or a related metalloprotease-disintegrin. TACE can cleave immunoprecipitated TRANCE in vitro at the same site used in intact cells. Soluble TRANCE retains potent dendritic cell survival and osteoclastogenic activity.","method":"Metalloprotease cleavage assay, in vitro TACE cleavage of immunoprecipitated TRANCE and ectodomain/CD8 fusion protein, N-terminal sequencing of cleavage site","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic cleavage assay with site identification, >300 citations","pmids":["10224132"],"is_preprint":false},{"year":1999,"finding":"Mouse RANKL/TRANCE/OPGL/ODF gene promoter contains inverted TATA- and CAAT-boxes, a Cbfa1/Osf2/AML3 binding domain, and repeated half-sites for vitamin D3 and glucocorticoid receptors at -935 and -640 bp respectively. Transient transfection showed that 1α,25(OH)2 VitD3 and dexamethasone increase promoter activity (~200% and ~178%), while CpG methylation in later-passage stromal cells correlates with loss of RANKL expression and osteoclastogenic support.","method":"Promoter cloning, transient transfection luciferase assay, genomic Southern blot, CpG methylation analysis","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — promoter characterization with functional reporter assays and methylation correlation","pmids":["10209265"],"is_preprint":false},{"year":2001,"finding":"Crystal structure of murine RANKL ectodomain at 2.6 Å resolution reveals a homotrimeric TNF-family scaffold with four unique surface loops that distinguish it from other TNF family members. Mutagenesis of selected residues in these loops significantly modulates RANK activation as measured by in vitro osteoclastogenesis, establishing these loops as specificity determinants for RANKL-RANK interaction.","method":"X-ray crystallography (2.6 Å), site-directed mutagenesis, in vitro osteoclastogenesis assay","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 — crystal structure combined with mutagenesis and functional validation","pmids":["11581298"],"is_preprint":false},{"year":2001,"finding":"RANKL ectodomain shedding in different cell types involves at least two distinct metalloprotease activities, both different from TACE: one is induced by the tyrosine phosphatase inhibitor pervanadate but not phorbol esters and is sensitive to TIMP-2 (consistent with a membrane-type MMP); the other is refractory to both stimuli. Cleavage site usage differs between these activities.","method":"Biochemical inhibitor profiling (TIMP-1, TIMP-2, phorbol ester, pervanadate), cleavage site mapping in multiple cell types","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological criteria distinguish activities, single lab","pmids":["11278735"],"is_preprint":false},{"year":2002,"finding":"IFN-γ produced by activated T cells inhibits RANKL-induced osteoclastogenesis by inducing rapid degradation of the RANK adapter protein TRAF6, thereby blocking NF-κB and JNK activation downstream of RANK. Separately, RANKL itself induces IFN-β (but not IFN-α) in osteoclast precursors, and IFN-β in turn inhibits osteoclast differentiation by interfering with RANKL-induced c-Fos expression—establishing a negative feedback loop.","method":"In vitro osteoclastogenesis, Western blot for TRAF6 degradation, NF-κB/JNK activation assays, IFN-β gene induction assay, c-Fos expression analysis","journal":"Arthritis research","confidence":"High","confidence_rationale":"Tier 2 — two distinct mechanistic pathways identified with direct biochemical measurements, in vivo validation mentioned","pmids":["12110142"],"is_preprint":false},{"year":2005,"finding":"MMP-7 produced by osteoclasts at the tumor-bone interface processes membrane-bound RANKL to a soluble form that promotes osteoclast activation and tumor-induced osteolysis. MMP-7-deficient mice demonstrate reduced prostate tumor-induced osteolysis and RANKL processing, establishing MMP-7 as a sheddase for RANKL in pathological bone resorption.","method":"Microarray, in vitro MMP-7 cleavage of RANKL, MMP-7 knockout mice, in vivo tumor-bone model, osteolysis measurement","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro enzymatic cleavage plus genetic (KO) in vivo validation, >270 citations","pmids":["15894268"],"is_preprint":false},{"year":2006,"finding":"RANKL triggers migration of RANK-expressing human epithelial cancer cells and melanoma cells; in vivo neutralization of RANKL by OPG in a mouse melanoma metastasis model provides complete protection from paralysis and marked reduction in bone tumor burden but not in other organs, establishing RANKL as a directional migration cue for RANK+ cancer cells mediating tissue-specific bone metastasis.","method":"In vitro migration assay with recombinant RANKL, in vivo mouse melanoma metastasis model with OPG neutralization, tumor burden measurement","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — in vitro functional assay + in vivo pharmacological neutralization with organ-specific readout, >600 citations","pmids":["16572175"],"is_preprint":false},{"year":2006,"finding":"Wnt signaling in osteoblasts transcriptionally represses RANKL (TNFSF11) gene expression through a β-catenin-dependent mechanism; overexpression of full-length but not transcriptionally inactive β-catenin inhibits RANKL promoter activity. Activation of Wnt signaling (LiCl or Wnt3a) in osteoblast-spleen cell co-cultures inhibits osteoclast formation without directly affecting osteoclast differentiation, survival, or activity in the absence of osteoblasts.","method":"Wnt3a and LiCl treatment of osteoblast/spleen cell co-cultures, β-catenin overexpression, RANKL promoter reporter assay, RANKL mRNA/protein measurement","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 — promoter reporter assay plus functional co-culture assay, replicated concept","pmids":["16522681"],"is_preprint":false},{"year":2007,"finding":"Loss-of-function mutations in the RANKL-encoding TNFSF11 gene cause autosomal recessive osteoclast-poor osteopetrosis in humans. Affected individuals lack osteoclasts in bone biopsies and cannot be cured by hematopoietic stem cell transplantation (confirming osteoclast precursors are not the primary defect), but exogenous RANKL induces functional osteoclast formation from their monocytes, demonstrating that RANKL is absolutely required for osteoclast differentiation in humans.","method":"Human genetics (mutation identification), bone biopsy histology, HSC transplantation outcome, exogenous RANKL rescue experiment on patient monocytes","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — human genetic loss-of-function with direct ex vivo rescue experiment","pmids":["17632511"],"is_preprint":false},{"year":2010,"finding":"RANK signaling in mammary carcinoma cells is required for pulmonary metastasis in Erbb2-transformed carcinoma; the major pro-metastatic RANKL source is tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells located adjacent to stromal cells. Exogenous RANKL stimulates pulmonary metastasis of RANK+ human breast cancer cells, and this dependence on T cells is replaceable by exogenous RANKL.","method":"In vivo mouse mammary tumor model, T cell depletion, exogenous RANKL administration, CD4+CD25+FOXP3+ T cell identification by flow cytometry and IHC","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple in vivo genetic and pharmacological approaches, >500 citations","pmids":["21326202"],"is_preprint":false},{"year":2010,"finding":"RANKL is the paracrine mediator of progestin-induced mammary epithelial proliferation and a direct contributor to mammary tumorigenesis. MMTV-RANK transgenic mice show accelerated pre-neoplasias and increased mammary tumors after multiparity or hormone/carcinogen treatment, while pharmacological RANKL inhibition attenuates mammary tumor development in multiple models by reducing hormone-induced mammary epithelial proliferation and cyclin D1 levels.","method":"MMTV-RANK transgenic mice, pharmacological RANKL inhibition, MMTV-neu spontaneous tumor model, in vivo tumor assessment, cyclin D1 measurement","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — complementary gain- and loss-of-function in vivo approaches, >480 citations","pmids":["20881963"],"is_preprint":false},{"year":2011,"finding":"Sclerostin produced by osteocytes dose-dependently upregulates RANKL mRNA and downregulates OPG mRNA in osteocyte-like cells, increasing osteoclastic resorption approximately 7-fold in co-cultures with splenocytes or PBMCs. This catabolic effect is abolished by OPG and sclerostin does not directly induce osteoclastogenesis from monocultures, establishing a RANKL-dependent mechanism by which osteocyte-derived sclerostin promotes bone resorption.","method":"Recombinant sclerostin treatment of osteocyte cultures, RANKL/OPG qPCR, co-culture osteoclastogenesis and resorption assay, OPG blocking","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — dose-response, OPG rescue, monoculture controls, >380 citations","pmids":["21991382"],"is_preprint":false},{"year":2015,"finding":"The human TNFSF11 locus contains a T cell control region (hTCCR) located between -170 and -220 kb upstream of the TSS that acts as a cell type-selective distal enhancer set for T cell-specific expression. ChIP-chip revealed histone acetylation enrichment and c-FOS recruitment to the hTCCR following TCR activation, and MEK1/2 signaling is required for RANKL induction in T cells. Both the RLD5a/b enhancer and hTCCR segments drove inducible reporter activity upon TCR stimulation.","method":"ChIP-chip, luciferase reporter assays, MEK1/2 inhibition (U0126), primary human T cells and Jurkat cells","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-chip plus functional reporter assays in primary cells, single lab","pmids":["25211367"],"is_preprint":false},{"year":2016,"finding":"Deletion of the distal Tnfsf11 RL-D2 enhancer (23 kb upstream of TSS) in mice significantly blunts PTH-induced RANKL expression in vivo, reduces skeletal RANKL expression, decreases osteoclast numbers, and produces a progressive high bone mass phenotype. Ex vivo, RL-D2-/- stromal cells show decreased RANKL induction by forskolin and 1,25(OH)2D3. CREB binding at RL-D2 is induced by PTH/cAMP signaling.","method":"ChIP-seq, enhancer deletion in mice, in vivo PTH challenge, ex vivo stromal cell culture, bone phenotyping by microCT","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo enhancer deletion with multiple physiological readouts and ex vivo validation","pmids":["26332516"],"is_preprint":false},{"year":2016,"finding":"Genetic inactivation of RANK in mammary epithelium or long-term pharmacological RANKL inhibition markedly delays onset, reduces incidence, and attenuates Brca1;p53 mutation-driven mammary cancer in mice. RANKL/RANK blockade impairs proliferation of murine Brca1;p53 mutant mammary stem cells and progenitors from human BRCA1 mutation carriers, placing RANKL-RANK signaling upstream of progenitor expansion in BRCA1-associated breast cancer.","method":"Conditional RANK knockout in mammary epithelium, pharmacological RANKL blockade, mammary stem cell and progenitor proliferation assays, human BRCA1-carrier tissue ex vivo","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 — two mouse models plus human tissue validation with mechanistic proliferation readout","pmids":["27241552"],"is_preprint":false},{"year":2016,"finding":"LOX does not substitute for RANKL in osteoclastogenesis. LOX fails to generate TRAP+ osteoclasts or resorption pits from RANKL-deficient or RANK-deficient cells; in wild-type cells, LOX synergizes with RANKL only by stimulating RANKL expression in bone marrow stromal cells via ROS production. LOX injection does not rescue the RANKL-deficient osteopetrotic phenotype in vivo.","method":"RANKL/RANK-deficient mouse cells, LOX treatment, TRAP staining, resorption pit assay, in vivo LOX injection into RANKL-KO mice, ROS measurement","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 — genetic null backgrounds plus in vivo rescue experiment, definitive negative evidence","pmids":["27606829"],"is_preprint":false},{"year":2017,"finding":"TRAF6 E3 ligase activity is not absolutely required for RANKL-induced osteoclastogenesis; RANKL-induced signaling in macrophages and bone marrow-to-osteoclast differentiation is normal in knockin mice expressing E3 ligase-inactive TRAF6[L74H], explaining the normal bone structure and teeth in these mice (unlike TRAF6 KO mice). This reveals that essential roles of TRAF6 in RANKL signaling are independent of its E3 ubiquitin ligase activity.","method":"TRAF6 E3 ligase-inactive knockin mice, osteoclastogenesis assay, bone phenotyping, macrophage RANKL signaling assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — knockin mouse genetic epistasis with in vitro and in vivo bone phenotype","pmids":["28404732"],"is_preprint":false},{"year":2021,"finding":"RANKL-stimulated osteoclasts do not exclusively undergo apoptosis after resorption; by intravital imaging, RANKL-stimulated osteoclasts undergo fission into daughter cells called osteomorphs. Inhibiting RANKL blocks this cellular recycling and causes osteomorph accumulation, establishing RANKL as a regulator of osteoclast recycling/fission in addition to differentiation.","method":"Intravital imaging, RANKL inhibition, single-cell RNA sequencing, genetic deletion of osteomorph-specific genes in mice","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — direct live imaging with pharmacological and genetic validation","pmids":["33636130"],"is_preprint":false},{"year":2022,"finding":"A druggable binding site on soluble RANKL (distinct from the membrane RANKL-RANK interface) was identified by molecular dynamics simulations; small molecule S3-15 selectively inhibits soluble RANKL-RANK interaction without interfering with membrane RANKL-RANK interaction, demonstrating conformational/functional differences between soluble and membrane-bound RANKL forms. S3-15 shows anti-osteoporotic effects in vivo without immunosuppression.","method":"Molecular dynamics simulation, in vitro binding assay (KD measurement), cell-based osteoclastogenesis assay, in vivo osteoporosis model, in silico and in vitro binding model validation","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — computational plus in vitro and in vivo validation, single lab","pmids":["36097003"],"is_preprint":false},{"year":2024,"finding":"In situ hybridization across species and skeletal sites reveals that under physiological conditions RANKL (Tnfsf11) is expressed mainly by osteoprogenitor bone surface cells proximate to osteoclasts, while OPG is expressed mainly by osteocytes and bone-forming osteoblasts. OPG:Fc treatment increases RANKL mRNA in trabecular bone surface cells and decreases OPG in bone surface cells/osteocytes, creating localized osteoclastogenic activation sites—explaining the denosumab rebound effect mechanistically.","method":"In situ hybridization across species and skeletal sites, OPG:Fc and PTH treatment of mice, single-cell RNA sequencing (public data reanalysis), co-expression analysis (Mmp13/Tnfsf11)","journal":"Bone research","confidence":"Medium","confidence_rationale":"Tier 2 — direct ISH localization with pharmacological perturbation, single lab but multi-species","pmids":["39424806"],"is_preprint":false}],"current_model":"TNFSF11 (RANKL) is a TNF-family type II transmembrane protein expressed on osteoblasts, osteocytes, stromal cells, activated T cells, and regulatory T cells; it exists in membrane-bound and proteolytically shed soluble forms (cleaved by TACE/ADAM17 and MMP-7 among others), signals through its receptor RANK via a complex involving TRAF6 and c-Src to activate NF-κB, JNK, Akt/PKB, p38 MAPK, and NFATc1, and is the essential and non-substitutable cytokine for osteoclast differentiation, activation, survival, and recycling (via osteomorph fission), while also regulating dendritic cell survival, lymph node organogenesis, mammary gland lobuloalveolar development and tumorigenesis, cancer cell migration to bone, and central thermoregulation."},"narrative":{"teleology":[{"year":1997,"claim":"Cloning of RANKL as a T-cell-expressed TNF-family ligand that activates JNK and regulates dendritic cell survival established the gene's identity and first biological functions outside bone.","evidence":"Expression cloning from activated T cells, JNK kinase assays, DC survival assays with dominant-negative TRAF2 transgenic mice","pmids":["9312132","9367155","9396779"],"confidence":"High","gaps":["Role in bone metabolism not yet recognized","Receptor on osteoclast lineage not identified","In vivo relevance to immune or skeletal homeostasis untested"]},{"year":1998,"claim":"Identification of RANKL as the osteoblast/stromal-cell-derived osteoclast differentiation factor (ODF/OPGL) resolved the longstanding question of how osteoblasts communicate with osteoclast precursors, showing that RANKL alone replaces stromal cells, vitamin D3, and glucocorticoids for osteoclastogenesis and causes hypercalcemia in vivo.","evidence":"Expression cloning from stromal cDNA library, reconstituted osteoclastogenesis without stromal cells, OPG blocking, in vivo mouse injection","pmids":["9520411","9568710"],"confidence":"High","gaps":["Whether RANKL is truly non-redundant in vivo required genetic proof","Downstream signaling cascade from RANK uncharacterized","Proteolytic processing and soluble form significance unknown"]},{"year":1999,"claim":"RANKL-knockout mice demonstrated absolute in vivo requirement for RANKL in osteoclast formation, tooth eruption, and lymph node organogenesis, while parallel biochemical studies delineated the RANK–TRAF6–c-Src–Akt signaling axis and identified TACE-mediated ectodomain shedding.","evidence":"RANKL-null mice (skeletal/immune phenotyping), co-IP and kinase assays in c-Src-deficient cells, in vitro TACE cleavage with N-terminal sequencing, osteoclast actin ring and resorption assays on bone slices","pmids":["9950424","10635328","10224132","10225954"],"confidence":"High","gaps":["Structural basis of RANKL-RANK specificity unknown","Whether additional sheddases exist beyond TACE","Negative feedback mechanisms limiting osteoclastogenesis undefined"]},{"year":2001,"claim":"The crystal structure of the RANKL trimer revealed unique surface loops that determine RANK-binding specificity, while additional sheddase activities distinct from TACE were shown to operate in different cell types, complicating the picture of soluble RANKL generation.","evidence":"X-ray crystallography at 2.6 Å with mutagenesis-coupled osteoclastogenesis, metalloprotease inhibitor profiling in multiple cell types","pmids":["11581298","11278735"],"confidence":"High","gaps":["Co-crystal structure of RANKL-RANK complex not yet solved","Identity of non-TACE sheddases not determined","Relative contributions of membrane-bound vs soluble RANKL to physiology unclear"]},{"year":2002,"claim":"Identification of IFN-γ-mediated TRAF6 degradation and RANKL-induced IFN-β negative feedback established that RANKL signaling is self-limiting, explaining how the immune and skeletal systems restrain osteoclastogenesis.","evidence":"In vitro osteoclastogenesis with Western blot for TRAF6 degradation, NF-κB/JNK and c-Fos expression analysis","pmids":["12110142"],"confidence":"High","gaps":["Quantitative contribution of IFN-β feedback vs IFN-γ to in vivo bone homeostasis unclear","Whether other negative regulators act at the same nodes not resolved"]},{"year":2005,"claim":"MMP-7 was identified as a pathologically relevant RANKL sheddase at the tumor-bone interface, directly linking proteolytic release of soluble RANKL to tumor-induced osteolysis.","evidence":"MMP-7 knockout mice with prostate tumor-bone model, in vitro MMP-7 cleavage of RANKL","pmids":["15894268"],"confidence":"High","gaps":["Whether MMP-7 cleaves RANKL at the same site as TACE not resolved","Relative contribution of MMP-7 vs other sheddases in non-tumor settings unknown"]},{"year":2006,"claim":"RANKL was shown to act as a chemotactic cue directing RANK-expressing cancer cells to bone, while Wnt/β-catenin signaling was found to repress RANKL transcription in osteoblasts—expanding RANKL's roles from differentiation factor to metastasis mediator and linking its expression to anabolic skeletal pathways.","evidence":"In vitro migration assay and in vivo melanoma metastasis model with OPG neutralization; β-catenin overexpression and Wnt3a/LiCl treatment of osteoblast co-cultures with RANKL promoter reporters","pmids":["16572175","16522681"],"confidence":"High","gaps":["Whether RANKL is sufficient or merely permissive for bone metastasis tropism","Full catalog of transcription factors controlling cell-type-specific RANKL expression incomplete"]},{"year":2007,"claim":"Human loss-of-function mutations in TNFSF11 were shown to cause autosomal recessive osteopetrosis, and patient monocytes formed osteoclasts when provided exogenous RANKL, proving RANKL is absolutely required for human osteoclastogenesis and that the defect lies in the microenvironment, not in precursor cells.","evidence":"Human genetic mutation identification, bone biopsy histology, failed HSC transplantation, ex vivo RANKL rescue of patient monocytes","pmids":["17632511"],"confidence":"High","gaps":["Whether partial loss-of-function alleles produce milder human skeletal phenotypes unknown","Immune consequences (lymph node, DC) of human RANKL deficiency incompletely characterized"]},{"year":2010,"claim":"RANKL was established as the paracrine mediator of progestin-driven mammary epithelial proliferation and tumorigenesis, with regulatory T cells identified as a major RANKL source promoting pulmonary metastasis of mammary carcinoma.","evidence":"MMTV-RANK transgenic mice, pharmacological RANKL inhibition in mammary tumor models, Treg depletion and RANKL add-back in vivo","pmids":["20881963","21326202"],"confidence":"High","gaps":["Whether RANKL drives mammary tumorigenesis independent of progesterone in humans not established","Molecular mechanism of RANKL-induced mammary progenitor expansion vs differentiation unclear"]},{"year":2016,"claim":"Dissection of distal enhancer elements (RL-D2) demonstrated how PTH/cAMP signaling controls RANKL expression in bone, while genetic RANK inactivation in mammary epithelium confirmed RANKL-RANK as a therapeutic target in BRCA1-associated breast cancer by restraining progenitor expansion.","evidence":"In vivo enhancer deletion in mice with PTH challenge and microCT; conditional RANK knockout and pharmacological RANKL blockade in Brca1;p53 mammary cancer models plus human BRCA1-carrier tissue","pmids":["26332516","27241552"],"confidence":"High","gaps":["Full enhancer landscape for RANKL in non-skeletal tissues (mammary, lymph node) not mapped","Clinical efficacy of RANKL inhibition for BRCA1-associated breast cancer prevention not yet demonstrated"]},{"year":2017,"claim":"The finding that TRAF6 E3 ubiquitin ligase activity is dispensable for RANKL-induced osteoclastogenesis revised the mechanistic model of RANK signaling, showing TRAF6 serves an essential scaffolding function independent of its catalytic activity.","evidence":"TRAF6 E3 ligase-inactive knockin mice with normal bone and osteoclastogenesis","pmids":["28404732"],"confidence":"High","gaps":["Which TRAF6 domain mediates the E3-independent scaffolding for RANK signaling unknown","Whether other E3 ligases compensate at the RANK signalosome not investigated"]},{"year":2021,"claim":"Intravital imaging revealed that RANKL-stimulated osteoclasts undergo fission into 'osteomorphs' rather than exclusively apoptosing, expanding RANKL's role from osteoclast formation to osteoclast lifecycle regulation and recycling.","evidence":"Intravital imaging of osteoclast fission, RANKL inhibition blocking recycling, scRNA-seq and genetic deletion of osteomorph-specific genes","pmids":["33636130"],"confidence":"High","gaps":["Signals that determine osteoclast fission vs apoptosis downstream of RANKL not identified","Whether osteomorphs contribute to bone-remodeling coupling signals unknown"]},{"year":2022,"claim":"Identification of a druggable binding site unique to soluble RANKL demonstrated that membrane-bound and soluble RANKL have conformational differences exploitable for selective inhibition, achieving anti-osteoporotic effects without immunosuppression in vivo.","evidence":"Molecular dynamics simulation, KD measurement, cell-based osteoclastogenesis assay, in vivo osteoporosis model with small molecule S3-15","pmids":["36097003"],"confidence":"Medium","gaps":["Independent replication of selective soluble-RANKL inhibitor efficacy not yet reported","Structural validation of the proposed soluble-RANKL-specific binding pocket by co-crystallography absent","Long-term safety and specificity of soluble-RANKL-selective inhibition not characterized"]},{"year":2024,"claim":"High-resolution in situ hybridization across species resolved that osteoprogenitor cells at the bone surface—not mature osteoblasts or osteocytes—are the primary physiological RANKL source, and that OPG:Fc treatment paradoxically upregulates local RANKL, providing a mechanistic explanation for the denosumab rebound phenomenon.","evidence":"Multi-species in situ hybridization, OPG:Fc and PTH treatment of mice, scRNA-seq reanalysis","pmids":["39424806"],"confidence":"Medium","gaps":["Whether the osteoprogenitor RANKL source dominance holds in pathological states (inflammation, cancer) not tested","Molecular mechanism of OPG:Fc-induced RANKL upregulation not delineated","Findings from single lab with limited human tissue validation"]},{"year":null,"claim":"Key unresolved questions include the precise signals distinguishing osteoclast fission from apoptosis downstream of RANKL, the full cis-regulatory architecture governing tissue-specific RANKL expression, the structural basis for soluble versus membrane-bound RANKL conformational differences, and whether selective soluble-RANKL inhibition can achieve clinical benefit in humans.","evidence":"","pmids":[],"confidence":"Low","gaps":["No co-crystal structure of RANKL–RANK complex at high resolution available","Enhancer landscape of RANKL in mammary and lymphoid tissues unmapped","Osteomorph biology and its regulation by RANKL poorly understood"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,3,4,5]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,9]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[9,14,27]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,8,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,7]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,17,19]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,26]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[15,18,19,23]}],"complexes":[],"partners":["TNFRSF11A","TNFRSF11B","TRAF6","SRC","ADAM17","MMP7","CTNNB1"],"other_free_text":[]},"mechanistic_narrative":"TNFSF11 (RANKL) is a type II transmembrane TNF-family cytokine that functions as the essential, non-substitutable ligand for RANK-mediated osteoclast differentiation, activation, survival, and recycling, while also regulating dendritic cell survival, lymph node organogenesis, and mammary epithelial proliferation [PMID:9520411, PMID:9950424, PMID:33636130, PMID:20881963]. Expressed predominantly by osteoblast-lineage cells, osteocytes, and activated T cells under the control of distal enhancers responsive to PTH/cAMP, vitamin D3, and TCR signaling, RANKL exists in membrane-bound and soluble forms generated by proteolytic shedding via TACE and MMP-7 [PMID:10224132, PMID:15894268, PMID:26332516, PMID:25211367]. Upon binding RANK, it assembles a signaling complex involving TRAF6 and c-Src that activates NF-κB, JNK, Akt/PKB, and NFATc1 to drive osteoclast gene programs, with IFN-β–mediated negative feedback restraining differentiation [PMID:10635328, PMID:12110142]. Loss-of-function mutations in human TNFSF11 cause autosomal recessive osteopetrosis characterized by absent osteoclasts, and RANKL–RANK signaling in RANK-expressing cancer cells promotes bone-tropic metastasis and BRCA1-mutation-driven mammary tumorigenesis [PMID:17632511, PMID:16572175, PMID:27241552]."},"prefetch_data":{"uniprot":{"accession":"O14788","full_name":"Tumor necrosis factor ligand superfamily member 11","aliases":["Osteoclast differentiation factor","ODF","Osteoprotegerin ligand","OPGL","Receptor activator of nuclear factor kappa-B ligand","RANKL","TNF-related activation-induced cytokine","TRANCE"],"length_aa":317,"mass_kda":35.5,"function":"Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy (PubMed:22664871). Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O14788/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFSF11","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFSF11","total_profiled":1310},"omim":[{"mim_id":"619820","title":"ATONAL bHLH TRANSCRIPTION FACTOR 8; ATOH8","url":"https://www.omim.org/entry/619820"},{"mim_id":"618749","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 17; LRRC17","url":"https://www.omim.org/entry/618749"},{"mim_id":"618107","title":"OSTEOPETROSIS, AUTOSOMAL DOMINANT 3; OPTA3","url":"https://www.omim.org/entry/618107"},{"mim_id":"617165","title":"PEROXIREDOXIN-LIKE 2A; PRXL2A","url":"https://www.omim.org/entry/617165"},{"mim_id":"616967","title":"THIOREDOXIN DOMAIN-CONTAINING PROTEIN 17; TXNDC17","url":"https://www.omim.org/entry/616967"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":3.9},{"tissue":"lymphoid tissue","ntpm":11.5}],"url":"https://www.proteinatlas.org/search/TNFSF11"},"hgnc":{"alias_symbol":["TRANCE","RANKL","OPGL","ODF","CD254"],"prev_symbol":[]},"alphafold":{"accession":"O14788","domains":[{"cath_id":"2.60.120.40","chopping":"166-316","consensus_level":"high","plddt":96.6026,"start":166,"end":316},{"cath_id":"1.20.5","chopping":"115-144","consensus_level":"high","plddt":71.7643,"start":115,"end":144}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14788","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14788-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14788-F1-predicted_aligned_error_v6.png","plddt_mean":79.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFSF11","jax_strain_url":"https://www.jax.org/strain/search?query=TNFSF11"},"sequence":{"accession":"O14788","fasta_url":"https://rest.uniprot.org/uniprotkb/O14788.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14788/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14788"}},"corpus_meta":[{"pmid":"9950424","id":"PMC_9950424","title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9950424","citation_count":2612,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11713196","id":"PMC_11713196","title":"Minireview: the OPG/RANKL/RANK system.","date":"2001","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11713196","citation_count":1046,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16356770","id":"PMC_16356770","title":"RANKL-RANK signaling in osteoclastogenesis and bone disease.","date":"2005","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16356770","citation_count":930,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17634140","id":"PMC_17634140","title":"Biology of RANK, RANKL, and osteoprotegerin.","date":"2007","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17634140","citation_count":689,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10225954","id":"PMC_10225954","title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10225954","citation_count":533,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33079279","id":"PMC_33079279","title":"Osteoclast differentiation by RANKL and OPG signaling pathways.","date":"2020","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33079279","citation_count":514,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10080918","id":"PMC_10080918","title":"A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10080918","citation_count":366,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33636130","id":"PMC_33636130","title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33636130","citation_count":288,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9600092","id":"PMC_9600092","title":"Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9600092","citation_count":278,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14969393","id":"PMC_14969393","title":"PTH differentially regulates expression of RANKL and OPG.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/14969393","citation_count":262,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17925190","id":"PMC_17925190","title":"The RANKL/RANK/OPG pathway.","date":"2007","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/17925190","citation_count":256,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17158225","id":"PMC_17158225","title":"MafB negatively regulates RANKL-mediated osteoclast differentiation.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17158225","citation_count":220,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16188502","id":"PMC_16188502","title":"Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.","date":"2005","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16188502","citation_count":212,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16313338","id":"PMC_16313338","title":"Osteoclast precursors, RANKL/RANK, and immunology.","date":"2005","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16313338","citation_count":185,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15615494","id":"PMC_15615494","title":"The OPG/RANKL/RANK system in metabolic bone diseases.","date":"2004","source":"Journal of musculoskeletal & neuronal interactions","url":"https://pubmed.ncbi.nlm.nih.gov/15615494","citation_count":182,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10380891","id":"PMC_10380891","title":"TRANCE is a TNF family member that regulates dendritic cell and osteoclast function.","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10380891","citation_count":166,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12379618","id":"PMC_12379618","title":"Role of RANKL and RANK in bone loss and arthritis.","date":"2002","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/12379618","citation_count":160,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33389131","id":"PMC_33389131","title":"Discovery of the RANKL/RANK/OPG system.","date":"2021","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33389131","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33895289","id":"PMC_33895289","title":"Hypoxia inhibits RANKL-induced ferritinophagy and protects osteoclasts from ferroptosis.","date":"2021","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33895289","citation_count":151,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25849336","id":"PMC_25849336","title":"RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.","date":"2015","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/25849336","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11581298","id":"PMC_11581298","title":"Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.","date":"2001","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11581298","citation_count":149,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22113597","id":"PMC_22113597","title":"Rank/Rankl/opg: literature review.","date":"2011","source":"Acta reumatologica portuguesa","url":"https://pubmed.ncbi.nlm.nih.gov/22113597","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27241552","id":"PMC_27241552","title":"RANKL/RANK control Brca1 mutation- .","date":"2016","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27241552","citation_count":138,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25720990","id":"PMC_25720990","title":"The RANKL-RANK Story.","date":"2015","source":"Gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/25720990","citation_count":138,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19191757","id":"PMC_19191757","title":"Action of RANKL and OPG for osteoclastogenesis.","date":"2009","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/19191757","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11521937","id":"PMC_11521937","title":"The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis.","date":"2001","source":"The Journal of bone and joint surgery. British volume","url":"https://pubmed.ncbi.nlm.nih.gov/11521937","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17530461","id":"PMC_17530461","title":"RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases.","date":"2007","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/17530461","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12110142","id":"PMC_12110142","title":"Signaling crosstalk between RANKL and interferons in osteoclast differentiation.","date":"2002","source":"Arthritis research","url":"https://pubmed.ncbi.nlm.nih.gov/12110142","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20571772","id":"PMC_20571772","title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","date":"2010","source":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","url":"https://pubmed.ncbi.nlm.nih.gov/20571772","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10209265","id":"PMC_10209265","title":"Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10209265","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21445556","id":"PMC_21445556","title":"RANKL/RANK-beyond bones.","date":"2011","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/21445556","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11278735","id":"PMC_11278735","title":"Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278735","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21196156","id":"PMC_21196156","title":"Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals.","date":"2011","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/21196156","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17634146","id":"PMC_17634146","title":"Clinical development of anti-RANKL therapy.","date":"2007","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17634146","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28404732","id":"PMC_28404732","title":"Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL signaling.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28404732","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23362465","id":"PMC_23362465","title":"Osteoclast fusion and regulation by RANKL-dependent and independent factors.","date":"2012","source":"World journal of orthopedics","url":"https://pubmed.ncbi.nlm.nih.gov/23362465","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35181574","id":"PMC_35181574","title":"RANKL biology.","date":"2022","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/35181574","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19762475","id":"PMC_19762475","title":"Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis.","date":"2009","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19762475","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33070252","id":"PMC_33070252","title":"RANKL and osteoimmunology in periodontitis.","date":"2020","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33070252","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19239825","id":"PMC_19239825","title":"Denosumab: anti-RANKL antibody.","date":"2009","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/19239825","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27456834","id":"PMC_27456834","title":"Proinflammatory M1 Macrophages Inhibit RANKL-Induced Osteoclastogenesis.","date":"2016","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27456834","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35902802","id":"PMC_35902802","title":"Artemisinin relieves osteoarthritis by activating mitochondrial autophagy through reducing TNFSF11 expression and inhibiting PI3K/AKT/mTOR signaling in cartilage.","date":"2022","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/35902802","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24929185","id":"PMC_24929185","title":"The immune system, bone and RANKL.","date":"2014","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/24929185","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24432249","id":"PMC_24432249","title":"Effects of RANKL-Targeted Therapy in Immunity and Cancer.","date":"2014","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24432249","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26659571","id":"PMC_26659571","title":"RANKL blockade prevents and treats aggressive osteosarcomas.","date":"2015","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26659571","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30929797","id":"PMC_30929797","title":"RANKL-independent modulation of osteoclastogenesis.","date":"2019","source":"Journal of oral biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/30929797","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16059638","id":"PMC_16059638","title":"BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.","date":"2005","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/16059638","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15785827","id":"PMC_15785827","title":"RANK, RANKL and osteoprotegerin in arthritic bone loss.","date":"2005","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/15785827","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25518928","id":"PMC_25518928","title":"MicroRNA-26a regulates RANKL-induced osteoclast formation.","date":"2014","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/25518928","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24719884","id":"PMC_24719884","title":"RANKL expression in periodontal disease: where does RANKL come from?","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24719884","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36513810","id":"PMC_36513810","title":"RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts.","date":"2022","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36513810","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27871200","id":"PMC_27871200","title":"Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.","date":"2016","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27871200","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32850393","id":"PMC_32850393","title":"Targeting the RANKL/RANK/OPG Axis for Cancer Therapy.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32850393","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20980052","id":"PMC_20980052","title":"RANKL-induced TRPV2 expression regulates osteoclastogenesis via calcium oscillations.","date":"2010","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/20980052","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21850548","id":"PMC_21850548","title":"Relationship between serum RANKL and RANKL in bone.","date":"2011","source":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","url":"https://pubmed.ncbi.nlm.nih.gov/21850548","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17634142","id":"PMC_17634142","title":"Role of RANKL inhibition in osteoporosis.","date":"2007","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17634142","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19661463","id":"PMC_19661463","title":"VEGF and RANKL regulation of NFATc1 in heart valve development.","date":"2009","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/19661463","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19299513","id":"PMC_19299513","title":"Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19299513","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15619676","id":"PMC_15619676","title":"RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.","date":"2004","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/15619676","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24477414","id":"PMC_24477414","title":"Regulatory mechanisms of RANKL presentation to osteoclast precursors.","date":"2014","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/24477414","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17539720","id":"PMC_17539720","title":"RANKL upregulation associated with periodontitis and Porphyromonas gingivalis.","date":"2007","source":"Journal of periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/17539720","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15940368","id":"PMC_15940368","title":"Annexin II stimulates RANKL expression through MAPK.","date":"2005","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/15940368","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16479591","id":"PMC_16479591","title":"Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts.","date":"2006","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16479591","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23665018","id":"PMC_23665018","title":"AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23665018","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34440747","id":"PMC_34440747","title":"The Roadmap of RANKL/RANK Pathway in Cancer.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34440747","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30804932","id":"PMC_30804932","title":"New Insights for RANKL as a Proinflammatory Modulator in Modeled Inflammatory Arthritis.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30804932","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27606829","id":"PMC_27606829","title":"LOX Fails to Substitute for RANKL in Osteoclastogenesis.","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/27606829","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36097003","id":"PMC_36097003","title":"Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36097003","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30609798","id":"PMC_30609798","title":"(-)-Epigallocatechin-3-Gallate Decreases Osteoclastogenesis via Modulation of RANKL and Osteoprotegrin.","date":"2019","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30609798","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39424806","id":"PMC_39424806","title":"Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect.","date":"2024","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/39424806","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21259010","id":"PMC_21259010","title":"The expression of RANKL and OPG in the various grades of osteoarthritic cartilage.","date":"2011","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/21259010","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22948539","id":"PMC_22948539","title":"Pulsed electromagnetic field stimulates osteoprotegerin and reduces RANKL expression in ovariectomized rats.","date":"2012","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/22948539","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29717113","id":"PMC_29717113","title":"CCL4 enhances preosteoclast migration and its receptor CCR5 downregulation by RANKL promotes osteoclastogenesis.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29717113","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27608420","id":"PMC_27608420","title":"IL-15 and RANKL Play a Synergistically Important Role in Osteoclastogenesis.","date":"2016","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27608420","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11137033","id":"PMC_11137033","title":"Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone.","date":"2001","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/11137033","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33994070","id":"PMC_33994070","title":"The hidden secrets of soluble RANKL in bone biology.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/33994070","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15615495","id":"PMC_15615495","title":"RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.","date":"2004","source":"Journal of musculoskeletal & neuronal interactions","url":"https://pubmed.ncbi.nlm.nih.gov/15615495","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21087090","id":"PMC_21087090","title":"Physiology and pathophysiology of the RANKL/RANK system.","date":"2010","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21087090","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21327765","id":"PMC_21327765","title":"Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.","date":"2011","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/21327765","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20633673","id":"PMC_20633673","title":"Association between radiographic hand osteoarthritis and RANKL, OPG and inflammatory markers.","date":"2010","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/20633673","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25694609","id":"PMC_25694609","title":"FOXO1 mediates RANKL-induced osteoclast formation and activity.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25694609","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23392729","id":"PMC_23392729","title":"Endotoxins potentiate COX-2 and RANKL expression in compressed PDL cells.","date":"2013","source":"Clinical oral investigations","url":"https://pubmed.ncbi.nlm.nih.gov/23392729","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30819183","id":"PMC_30819183","title":"Adiponectin regulates bone mass in AIS osteopenia via RANKL/OPG and IL6 pathway.","date":"2019","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30819183","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25211367","id":"PMC_25211367","title":"Transcriptional regulation of the human TNFSF11 gene in T cells via a cell type-selective set of distal enhancers.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25211367","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22023901","id":"PMC_22023901","title":"The RANKL pathway and denosumab.","date":"2011","source":"Rheumatic diseases clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/22023901","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26332516","id":"PMC_26332516","title":"Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice.","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/26332516","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27783278","id":"PMC_27783278","title":"Can we prevent BRCA1-associated breast cancer by RANKL inhibition?","date":"2016","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/27783278","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29259683","id":"PMC_29259683","title":"RANKL system in vascular and valve calcification with aging.","date":"2016","source":"Inflammation and regeneration","url":"https://pubmed.ncbi.nlm.nih.gov/29259683","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18685382","id":"PMC_18685382","title":"RANKL signaling in bone physiology and cancer.","date":"2007","source":"Current opinion in supportive and palliative care","url":"https://pubmed.ncbi.nlm.nih.gov/18685382","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16730419","id":"PMC_16730419","title":"Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women.","date":"2006","source":"Maturitas","url":"https://pubmed.ncbi.nlm.nih.gov/16730419","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32971123","id":"PMC_32971123","title":"Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.","date":"2020","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/32971123","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28733136","id":"PMC_28733136","title":"Unexpected Bone Formation Produced by RANKL Blockade.","date":"2017","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/28733136","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20446027","id":"PMC_20446027","title":"Porphyromonas gingivalis induces RANKL in T-cells.","date":"2011","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/20446027","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20531232","id":"PMC_20531232","title":"TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women.","date":"2010","source":"Menopause (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20531232","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28245593","id":"PMC_28245593","title":"TNFα Increases RANKL Expression via PGE₂-Induced Activation of NFATc1.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28245593","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24820666","id":"PMC_24820666","title":"NOD2 Mediates Odontoblast Differentiation and RANKL Expression.","date":"2014","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/24820666","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20602239","id":"PMC_20602239","title":"Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children.","date":"2010","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/20602239","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29741640","id":"PMC_29741640","title":"RANKL/RANK Pathway and Its Inhibitor RANK-Fc in Uterine Leiomyoma Growth.","date":"2018","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29741640","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21501964","id":"PMC_21501964","title":"Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Paget's disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms.","date":"2011","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21501964","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25256217","id":"PMC_25256217","title":"PKCβ positively regulates RANKL-induced osteoclastogenesis by inactivating GSK-3β.","date":"2014","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/25256217","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9568710","id":"PMC_9568710","title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9568710","citation_count":4243,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9520411","id":"PMC_9520411","title":"Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9520411","citation_count":3272,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21102463","id":"PMC_21102463","title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21102463","citation_count":2036,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9367155","id":"PMC_9367155","title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9367155","citation_count":1763,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10580503","id":"PMC_10580503","title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10580503","citation_count":1450,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9312132","id":"PMC_9312132","title":"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9312132","citation_count":822,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9396779","id":"PMC_9396779","title":"TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9396779","citation_count":673,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16572175","id":"PMC_16572175","title":"Regulation of cancer cell migration and bone metastasis by RANKL.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16572175","citation_count":634,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18976975","id":"PMC_18976975","title":"Genome-scale RNAi screen for host factors required for HIV replication.","date":"2008","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/18976975","citation_count":627,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21326202","id":"PMC_21326202","title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21326202","citation_count":545,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10635328","id":"PMC_10635328","title":"TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10635328","citation_count":502,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18445777","id":"PMC_18445777","title":"Multiple genetic loci for bone mineral density and fractures.","date":"2008","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18445777","citation_count":485,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20881963","id":"PMC_20881963","title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20881963","citation_count":480,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21991382","id":"PMC_21991382","title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21991382","citation_count":386,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15564564","id":"PMC_15564564","title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.","date":"2004","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/15564564","citation_count":383,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15304486","id":"PMC_15304486","title":"Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15304486","citation_count":351,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10224132","id":"PMC_10224132","title":"Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10224132","citation_count":326,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17632511","id":"PMC_17632511","title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17632511","citation_count":279,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15894268","id":"PMC_15894268","title":"MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.","date":"2005","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/15894268","citation_count":278,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19079262","id":"PMC_19079262","title":"New sequence variants associated with bone mineral density.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19079262","citation_count":274,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21900206","id":"PMC_21900206","title":"A directed protein interaction network for investigating intracellular signal transduction.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21900206","citation_count":258,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16522681","id":"PMC_16522681","title":"Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.","date":"2006","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/16522681","citation_count":256,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22705116","id":"PMC_22705116","title":"New insights into osteoclastogenic signaling mechanisms.","date":"2012","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/22705116","citation_count":252,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48329,"output_tokens":6636,"usd":0.122263},"stage2":{"model":"claude-opus-4-6","input_tokens":10318,"output_tokens":4315,"usd":0.239198},"total_usd":0.748446,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":61300,"output_tokens":7434,"usd":0.147705},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11404,"output_tokens":4100,"usd":0.23928}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"OPGL/RANKL is an essential osteoclast differentiation factor in vivo; mice with disrupted opgl gene show severe osteopetrosis, completely lack osteoclasts due to inability of osteoblasts to support osteoclastogenesis, exhibit defects in early T and B lymphocyte differentiation, and lack all lymph nodes, establishing OPGL as a regulator of lymph-node organogenesis and lymphocyte development.\",\n      \"method\": \"Gene knockout mouse (opgl-deficient mice) with skeletal, lymphoid, and dental phenotypic analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo genetic loss-of-function with multiple orthogonal phenotypic readouts; foundational paper with >2600 citations\",\n      \"pmids\": [\"9950424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"OPGL/RANKL binds specifically to mature osteoclasts via its receptor RANK, rapidly induces actin ring formation (cytoskeletal rearrangement prerequisite for bone resorption) within 30 minutes, and increases total bone surface erosion ~7-fold; OPG blocks both actin ring formation and bone resorption, demonstrating direct activation of mature osteoclasts independent of effects on precursors.\",\n      \"method\": \"Primary rat osteoclast culture on bone slices, scanning electron microscopy, in vivo calcium measurement, antibody blocking experiments\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro and in vivo methods with functional readouts; >530 citations\",\n      \"pmids\": [\"10225954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Soluble ODF/RANKL induces osteoclast-like multinucleated cell formation from human peripheral blood mononuclear cells in the presence of M-CSF, without requiring osteoblasts/stromal cells; OCIF/OPG acts as a naturally occurring decoy receptor for ODF, inhibiting signal transduction in human osteoclast formation.\",\n      \"method\": \"Human PBMC culture with recombinant sODF and M-CSF; TRACP staining, calcitonin response, resorption pit assay, OPG inhibition\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays in human cells, replicated mechanism; >270 citations\",\n      \"pmids\": [\"9600092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Crystal structure of murine RANKL ectodomain at 2.6 Å resolution reveals it self-associates as a homotrimer with four unique surface loops distinguishing it from other TNF family cytokines; mutagenesis of residues in these loops significantly modulates RANK activation as measured by in vitro osteoclastogenesis, establishing structural determinants of RANKL-RANK specificity.\",\n      \"method\": \"X-ray crystallography (2.6 Å resolution) and site-directed mutagenesis with in vitro osteoclastogenesis assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis with functional validation in a single study\",\n      \"pmids\": [\"11581298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RANKL undergoes ectodomain shedding by at least two distinct metalloprotease activities (sheddases) that differ from TNF-alpha convertase (TACE): one is induced by pervanadate (tyrosine phosphatase inhibitor) and sensitive to TIMP-2 (consistent with a membrane-type MMP), while the other is refractory to pervanadate and phorbol esters, potentially converting membrane-bound RANKL to a soluble paracrine form.\",\n      \"method\": \"Biochemical characterization of shedding cleavage sites, stimulator/inhibitor pharmacology, TIMP sensitivity assays in multiple cell types\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzymatic characterization with multiple orthogonal criteria (cleavage site, pharmacology, TIMP sensitivity)\",\n      \"pmids\": [\"11278735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The RANKL/TRANCE/OPGL/ODF gene promoter contains inverted TATA- and CAAT-boxes, a Cbfa1/Osf2/AML3 binding domain, and repeated half-sites for vitamin D3 and glucocorticoid receptors at -935 and -640 respectively; transient transfection showed that 1α,25(OH)2 VitD3 and dexamethasone increase promoter activity ~2-fold, while CpG methylation in later-passage stromal cells that lost osteoclastogenic support correlates with gene silencing.\",\n      \"method\": \"5'-flanking region cloning, transient transfection/luciferase reporter assay, genomic Southern blot, CpG methylation analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter functional analysis with multiple methods in single lab\",\n      \"pmids\": [\"10209265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IFN-γ produced by activated T cells inhibits RANKL-induced osteoclastogenesis by inducing rapid degradation of the RANK adapter protein TRAF6, thereby blocking RANKL-induced NF-κB and JNK activation; independently, RANKL induces IFN-β (but not IFN-α) expression in osteoclast precursors, and IFN-β strongly inhibits osteoclast differentiation by interfering with RANKL-induced c-Fos expression.\",\n      \"method\": \"Signaling pathway analysis (TRAF6 degradation, NF-κB/JNK activation), gene expression studies, in vivo experiments with IFN-deficient mice\",\n      \"journal\": \"Arthritis research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with multiple signaling readouts and in vivo validation; >120 citations\",\n      \"pmids\": [\"12110142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MafB negatively regulates RANKL-induced osteoclast differentiation: RANKL reduces MafB expression during osteoclastogenesis; MafB overexpression inhibits TRAP+ multinuclear osteoclast formation and attenuates NFATc1 and OSCAR gene induction; MafB proteins directly interfere with DNA-binding ability of c-Fos, Mitf, and NFATc1 to inhibit their transactivation; MafB knockdown by RNAi enhances osteoclastogenesis.\",\n      \"method\": \"Overexpression and RNAi knockdown in bone marrow-derived monocyte/macrophage cells, gene expression analysis, DNA-binding interference assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with mechanistic molecular dissection; >220 citations\",\n      \"pmids\": [\"17158225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PTH differentially regulates RANKL and OPG expression depending on osteoblast differentiation stage: PTH significantly upregulates RANKL mRNA in mature osteoblasts (days 21–28) while inhibiting OPG gene expression at all stages; these changes are associated with increased osteoclastogenesis in co-culture, with PTH's osteoclastogenic activity occurring primarily through OPG suppression early and RANKL elevation late in differentiation.\",\n      \"method\": \"Quantitative real-time RT-PCR of RANKL, OPG, and differentiation markers in mouse primary bone marrow stromal cells across 28-day culture; TRACP+ cell counting in co-culture\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — qRT-PCR with functional co-culture validation across differentiation time course\",\n      \"pmids\": [\"14969393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TRAF6 E3 ligase activity is not essential for RANKL-induced signaling in macrophages or osteoclast differentiation from bone marrow; RANKL-induced osteoclastogenesis and bone structure are normal in TRAF6[L74H] E3 ligase-inactive knockin mice, identifying E3 ligase-independent roles of TRAF6 in RANKL signaling.\",\n      \"method\": \"TRAF6 E3 ligase-inactive knockin mice (TRAF6[L74H]), osteoclast differentiation assays, bone structure analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic knockin with mechanistic epistasis establishing TRAF6 E3-independent RANKL signaling\",\n      \"pmids\": [\"28404732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RANKL upregulates TRPV2 expression in preosteoclasts, which contributes to Ca2+ oscillations required for NFATc1 activation and osteoclast differentiation; TRPV2 silencing and TRPV inhibitor ruthenium red significantly decreased Ca2+ oscillation frequency, inward cation currents, NFATc1 expression, NFATc1 nuclear translocation, and osteoclastogenesis in RANKL-treated RAW264.7 cells.\",\n      \"method\": \"DNA microarray, siRNA knockdown, electrophysiology (patch clamp), live cell calcium imaging, NFATc1 localization\",\n      \"journal\": \"Cell calcium\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (microarray, siRNA, electrophysiology, imaging) in single study\",\n      \"pmids\": [\"20980052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RANKL acts as a survival factor in mature osteoclasts by downregulating Fas expression and Fas-mediated apoptosis through NF-κB: in osteoclast precursors, RANKL upregulates Fas promoter activity via NF-κB binding; in differentiated osteoclasts, RANKL reduces Fas protein and mRNA levels in a concentration-dependent manner, protecting from Fas-induced apoptosis.\",\n      \"method\": \"Western blotting, RT-PCR, flow cytometry, luciferase reporter assay, EMSA (NF-κB binding to Fas promoter), caspase-3 activity assay\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical methods with mechanistic promoter analysis\",\n      \"pmids\": [\"15619676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Genetic inactivation of RANK in mammary epithelium markedly delayed onset, reduced incidence, and attenuated progression of Brca1;p53 mutation-driven mammary cancer; RANKL/RANK blockade impaired proliferation and expansion of murine Brca1;p53 mutant mammary stem cells and mammary progenitors from human BRCA1 mutation carriers; long-term pharmacological RANKL inhibition abolished Brca1 mutation-driven pre-neoplastic lesions.\",\n      \"method\": \"Conditional mammary epithelium-specific Rank knockout mice, RANKL pharmacological blockade, mammary stem/progenitor cell proliferation assays\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic and pharmacological loss-of-function with mechanistic cellular readouts; >135 citations\",\n      \"pmids\": [\"27241552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RANKL blockade (RANK-Fc) arrests osteosarcoma tumor progression, improves survival, and inhibits lung metastasis in genetically engineered mouse models (GEMMs) with osteoblast-specific Rb, p53, and Prkar1α deletions that exhibit RANKL and osteoclast hyperactivity; whole-body Rankl deletion completely abrogates tumorigenesis; osteoclastic Rank deletion delays tumorigenesis and is associated with PTEN upregulation.\",\n      \"method\": \"Conditional knockout GEMMs, whole-body Rankl deletion, RANK-Fc pharmacological treatment, tumor progression and survival analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis and pharmacological intervention with multiple mechanistic readouts\",\n      \"pmids\": [\"26659571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LOX induces RANKL expression on bone marrow stromal cells via reactive oxygen species (ROS) production but fails to substitute for RANKL in osteoclastogenesis; LOX treatment of RANKL-deficient or RANK-deficient cells does not produce TRAP+ osteoclasts or resorption pits, and LOX injection fails to rescue the phenotype of RANKL-deficient mice, proving that LOX-induced osteoclastogenesis is entirely RANKL-dependent.\",\n      \"method\": \"RANKL- and RANK-deficient mouse cells, LOX treatment, TRAP staining, resorption pit assay, RANKL-deficient mouse in vivo rescue experiments, ROS measurement\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function (RANKL-KO and RANK-KO) with in vitro and in vivo epistasis\",\n      \"pmids\": [\"27606829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RANKL-stimulated osteoclasts undergo cellular fission into daughter cells called osteomorphs as an alternative cell fate to apoptosis; inhibiting RANKL blocked this cellular recycling and caused osteomorph accumulation; single-cell RNA sequencing showed osteomorphs are transcriptionally distinct from osteoclasts and macrophages.\",\n      \"method\": \"Intravital imaging, RANKL inhibition, single-cell RNA sequencing\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — intravital imaging plus scRNA-seq with RANKL inhibition intervention; >285 citations\",\n      \"pmids\": [\"33636130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The human TNFSF11 gene in T cells is regulated through distal enhancers located between -170 and -220 kb upstream of the TSS (human T cell control region, hTCCR); MEK1/2 signaling is required for RANKL induction (U0126 inhibition decreases expression); c-FOS is recruited to the hTCCR; both the RLD5a/b enhancer and hTCCR segments mediate inducible reporter activity following TCR activation.\",\n      \"method\": \"ChIP-chip analysis for histone H3/H4 acetylation, MEK1/2 inhibitor treatment, c-FOS ChIP, luciferase reporter assays in Jurkat cells and primary human T cells\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-chip and functional reporter assays in single lab\",\n      \"pmids\": [\"25211367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Deletion of the distal Tnfsf11 RL-D2 enhancer (23 kb upstream of TSS) blunts PTH-induced RANKL expression in osteoblastic cells and in vivo, decreases osteoclast numbers, and produces a progressive high bone mass phenotype; CREB and VDR bind this enhancer in response to cAMP and 1,25(OH)2D3 respectively.\",\n      \"method\": \"ChIP-seq, CRISPR/genomic enhancer deletion in mice, ex vivo stromal cell RANKL induction assays, in vivo PTH and VitD3 challenges, microCT bone analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo enhancer deletion with multiple mechanistic readouts (ChIP-seq, gene expression, bone phenotype)\",\n      \"pmids\": [\"26332516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RANKL induces formation of ~200 superenhancers (SEs) and suppresses 148 SEs in macrophages; RANKL-responsive SEs are correlated with osteoclastogenic gene programs and selectively enriched in human osteoclasts; BATF1/3 binding motifs are enriched in RANKL-responsive SEs, and BATF1/3 depletion inhibits RANKL-induced osteoclast differentiation; SE-associated enhancer RNAs (SE-eRNAs) near NFATc1 are induced by RANKL and their knockdown suppresses NFATc1 expression and osteoclastogenesis.\",\n      \"method\": \"ChIP-seq, ATAC-seq, nuclear RNA-seq, PRO-seq, siRNA knockdown, BET protein inhibition\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide multi-omics with functional siRNA validation; multiple orthogonal methods in single study\",\n      \"pmids\": [\"36513810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXO1 expression and nuclear localization is induced by RANKL in osteoclast precursors; lineage-specific FOXO1 deletion (LyzM.Cre+FOXO1L/L) reduces RANKL-induced osteoclast formation and activity by ~50% in vivo and in vitro; FOXO1 mediates RANKL effects via regulation of NFATc1 nuclear localization/expression and downstream factors (DC-STAMP, ATP6vod2, cathepsin K, integrin αv); FOXO1 deletion also reduces M-CSF-induced RANK expression and osteoclast precursor migration.\",\n      \"method\": \"Conditional lineage-specific knockout mice, siRNA knockdown in RAW264.7, gene expression analysis, NFATc1 localization\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo conditional knockout with in vitro mechanistic corroboration\",\n      \"pmids\": [\"25694609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-26a is upregulated by RANKL at the late stage of osteoclastogenesis; miR-26a mimic suppresses osteoclast formation, actin-ring formation, and bone resorption by targeting CTGF/CCN2, which promotes osteoclastogenesis via DC-STAMP upregulation; miR-26a inhibitor enhances RANKL-induced osteoclastogenesis.\",\n      \"method\": \"miRNA mimic/inhibitor transfection, RT-PCR, bone resorption assay, rescue with recombinant CTGF\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab with gain/loss-of-function and rescue experiment\",\n      \"pmids\": [\"25518928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PKCβ is upregulated by RANKL and positively regulates osteoclastogenesis by phosphorylating (inactivating) GSK-3β, leading to NFATc1 induction; PKCβ pharmacological inhibition and RNA interference both suppress osteoclast differentiation, NFATc1 induction, and GSK-3β phosphorylation; in vivo PKC inhibitor administration protected against RANKL-induced calvarial bone destruction.\",\n      \"method\": \"Pharmacological inhibition, RNA interference, phosphorylation analysis, in vivo calvarial bone destruction model\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — multiple in vitro methods with in vivo validation, single lab\",\n      \"pmids\": [\"25256217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TNFα increases RANKL expression via PGE2-mediated activation of NFATc1 and CREB: TNFα induces COX2-dependent PGE2 production; PGE2 acts through EP2/EP4 receptors to activate NFAT transcriptional activity; both NFATc1 and CREB bind the RANKL promoter following TNFα/PGE2 stimulation; mutations in the NFAT-binding element or CRE-like element suppress TNFα-induced RANKL promoter activity.\",\n      \"method\": \"Luciferase reporter assay with promoter mutations, ChIP for NFATc1/CREB binding, PGE2 receptor antagonists, COX inhibition, calcineurin/NFAT pathway inhibitors\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic promoter dissection with multiple inhibitors and ChIP, single lab\",\n      \"pmids\": [\"28245593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RANKL/RANK signaling promotes uterine leiomyoma cell proliferation: RANKL mRNA is higher in leiomyoma than myometrium; RANK is highest in leiomyoma stem cells; RANKL is highest in progesterone receptor (PR)-rich intermediate cells and is upregulated by PR agonist R5020; RANK-Fc blocks RANKL-induced cyclin D1 expression and significantly decreases tumor growth in human xenograft model in vivo.\",\n      \"method\": \"mRNA/protein quantification, PR agonist treatment, RANK-Fc blocking, human xenograft mouse model, Ki67 proliferation marker\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo functional studies with mechanistic molecular readouts, single lab\",\n      \"pmids\": [\"29741640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In situ hybridization directly identified bone surface cells (osteoprogenitors co-expressing Tnfsf11/RANKL and Mmp13) as the primary activators of osteoclastogenesis in trabecular bone; osteocytes and bone-forming osteoblasts are the primary OPG expressers; OPG:Fc treatment increases RANKL mRNA in trabecular bone surface cells while decreasing OPG in both bone surface cells and osteocytes, creating an accumulation of osteoclastogenic activation sites that may explain the denosumab rebound effect.\",\n      \"method\": \"In situ hybridization across species/skeletal sites, OPG:Fc and PTH treatment of mice, scRNA-seq data analysis\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct in situ localization with pharmacological perturbation and multi-species validation\",\n      \"pmids\": [\"39424806\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFSF11/RANKL, a TNF superfamily cytokine expressed as a membrane-bound and shed soluble form by osteoblast-lineage cells (principally bone surface cells and osteocytes), binds its receptor RANK on osteoclast precursors and mature osteoclasts to drive osteoclast differentiation (via NFATc1, c-Fos, TRAF6, and ITAM co-stimulatory signals), directly activate mature osteoclasts through actin ring formation, and promote osteoclast survival by suppressing Fas-mediated apoptosis via NF-κB; OPG acts as a soluble decoy receptor that competitively blocks RANKL–RANK interaction; beyond bone, RANKL/RANK signaling is required for lymph-node organogenesis, mammary gland lactational development, mammary progenitor expansion and hormone-driven breast tumorigenesis, central thermoregulation, and contributes to uterine leiomyoma growth, with RANKL expression controlled by distal enhancers (RL-D2, RL-D5, hTCCR) responding to PTH, vitamin D3, glucocorticoids, and T-cell receptor activation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"TRANCE (RANKL/TNFSF11) was cloned as a type II membrane protein of 316 amino acids expressed on activated T cells; its ectodomain activated c-Jun N-terminal kinase (JNK) in T cells upon interaction with its receptor, and its expression was controlled by calcineurin-regulated transcription factors downstream of TCR stimulation.\",\n      \"method\": \"Somatic cell genetic cloning, recombinant protein production, JNK kinase assay, Northern blot, chromosomal mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning paper with direct biochemical assays (JNK activation), replicated across multiple labs\",\n      \"pmids\": [\"9312132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"RANKL (TRANCE) was identified as the ligand for the receptor RANK on dendritic cells; RANKL augments dendritic cell ability to stimulate naive T-cell proliferation and increases survival of RANK+ T cells, establishing RANKL-RANK as a regulator of T cell–dendritic cell interactions.\",\n      \"method\": \"Direct expression cloning, mixed lymphocyte reaction, cell survival assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original discovery paper with functional assays, highly cited and replicated\",\n      \"pmids\": [\"9367155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRANCE (RANKL) acts as a dendritic cell-specific survival factor by signaling through TRANCE-R (RANK) in a TRAF2-dependent manner, upregulating Bcl-xL expression to inhibit apoptosis of bone marrow-derived and monocyte-derived dendritic cells.\",\n      \"method\": \"In vitro DC survival assay, dominant-negative TRAF2 transgenic mice, Bcl-xL Western blot\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic (transgenic) and biochemical evidence, highly cited\",\n      \"pmids\": [\"9396779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RANKL (ODF/OPGL) was identified as the osteoblast/stromal cell membrane-bound ligand for OPG/OCIF, functioning as the osteoclast differentiation factor (ODF). Soluble ectodomain of ODF induced osteoclast-like cell formation from spleen cells in the absence of osteoblasts/stromal cells, and this was blocked by OPG. RANKL expression in osteoblasts/stromal cells was upregulated by bone-resorbing factors.\",\n      \"method\": \"Expression cloning from stromal cell cDNA library, in vitro osteoclastogenesis assay, OPG blocking experiment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational cloning and reconstitution experiment, independently replicated, >3000 citations\",\n      \"pmids\": [\"9520411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RANKL (OPGL) is a TNF-related cytokine that replaces the requirement for stromal cells, vitamin D3, and glucocorticoids in osteoclastogenesis. It binds to a hematopoietic progenitor committed to the osteoclast lineage, stimulates rapid induction of osteoclast-specific genes, directly activates isolated mature osteoclasts in vitro, and causes systemic hypercalcemia when administered to mice in vivo. Its effects are blocked by OPG in vitro and in vivo.\",\n      \"method\": \"Recombinant protein production, in vitro osteoclastogenesis, gene expression analysis, in vivo mouse injection, OPG neutralization\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in vitro and in vivo validation, >4000 citations\",\n      \"pmids\": [\"9568710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RANKL (OPGL) directly binds to and activates mature osteoclasts via RANK, inducing actin ring formation within 30 minutes—a cytoskeletal rearrangement required for bone resorption—and increases total bone surface erosion approximately 7-fold. Anti-RANK antibodies also induce actin ring formation, confirming RANK as the mediating receptor. OPG blocks these effects.\",\n      \"method\": \"Primary rat osteoclast culture on bone slices, scanning electron microscopy, actin ring immunofluorescence, antibody blocking\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct mechanistic experiment on mature osteoclasts with multiple orthogonal readouts\",\n      \"pmids\": [\"10225954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RANKL-deficient (opgl-null) mice completely lack osteoclasts due to inability of osteoblasts to support osteoclastogenesis, show severe osteopetrosis, defective tooth eruption, defects in early T and B lymphocyte differentiation, and absence of all lymph nodes. This genetic evidence establishes RANKL as an essential osteoclast differentiation factor in vivo and a regulator of lymph node organogenesis.\",\n      \"method\": \"Gene knockout in mice, skeletal and immunological phenotyping, histology\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — definitive in vivo loss-of-function, multiple phenotypes, >2600 citations\",\n      \"pmids\": [\"9950424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Activated T cells directly trigger osteoclastogenesis through RANKL expression; systemic T cell activation in vivo causes RANKL-mediated increases in osteoclastogenesis and bone loss. In a rat adjuvant arthritis model, OPG treatment blocking RANKL prevents bone and cartilage destruction but not inflammation, establishing that T-cell-derived RANKL drives pathological bone resorption.\",\n      \"method\": \"T cell activation in vivo, OPG treatment in rat adjuvant arthritis model, histology, bone density measurement\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic and pharmacological epistasis, >1400 citations\",\n      \"pmids\": [\"10580503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TRANCE (RANKL) activates the antiapoptotic kinase Akt/PKB in osteoclasts through a signaling complex at TRANCE-R (RANK) that involves TRAF6 and c-Src. c-Src deficiency or Src-family kinase inhibitors block TRANCE-mediated PKB activation. TRAF6 and c-Src interact with each other and with TRANCE-R upon receptor engagement; TRAF6 enhances c-Src kinase activity, leading to tyrosine phosphorylation of c-Cbl.\",\n      \"method\": \"Co-immunoprecipitation, kinase assays, c-Src-deficient cells, pharmacological Src inhibitors\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical reconstitution of signaling complex, genetic validation, >500 citations\",\n      \"pmids\": [\"10635328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TRANCE (RANKL) is shed from the plasma membrane as a soluble form by a metalloprotease activity consistent with TACE (TNF-alpha converting enzyme) or a related metalloprotease-disintegrin. TACE can cleave immunoprecipitated TRANCE in vitro at the same site used in intact cells. Soluble TRANCE retains potent dendritic cell survival and osteoclastogenic activity.\",\n      \"method\": \"Metalloprotease cleavage assay, in vitro TACE cleavage of immunoprecipitated TRANCE and ectodomain/CD8 fusion protein, N-terminal sequencing of cleavage site\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic cleavage assay with site identification, >300 citations\",\n      \"pmids\": [\"10224132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Mouse RANKL/TRANCE/OPGL/ODF gene promoter contains inverted TATA- and CAAT-boxes, a Cbfa1/Osf2/AML3 binding domain, and repeated half-sites for vitamin D3 and glucocorticoid receptors at -935 and -640 bp respectively. Transient transfection showed that 1α,25(OH)2 VitD3 and dexamethasone increase promoter activity (~200% and ~178%), while CpG methylation in later-passage stromal cells correlates with loss of RANKL expression and osteoclastogenic support.\",\n      \"method\": \"Promoter cloning, transient transfection luciferase assay, genomic Southern blot, CpG methylation analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter characterization with functional reporter assays and methylation correlation\",\n      \"pmids\": [\"10209265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Crystal structure of murine RANKL ectodomain at 2.6 Å resolution reveals a homotrimeric TNF-family scaffold with four unique surface loops that distinguish it from other TNF family members. Mutagenesis of selected residues in these loops significantly modulates RANK activation as measured by in vitro osteoclastogenesis, establishing these loops as specificity determinants for RANKL-RANK interaction.\",\n      \"method\": \"X-ray crystallography (2.6 Å), site-directed mutagenesis, in vitro osteoclastogenesis assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure combined with mutagenesis and functional validation\",\n      \"pmids\": [\"11581298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RANKL ectodomain shedding in different cell types involves at least two distinct metalloprotease activities, both different from TACE: one is induced by the tyrosine phosphatase inhibitor pervanadate but not phorbol esters and is sensitive to TIMP-2 (consistent with a membrane-type MMP); the other is refractory to both stimuli. Cleavage site usage differs between these activities.\",\n      \"method\": \"Biochemical inhibitor profiling (TIMP-1, TIMP-2, phorbol ester, pervanadate), cleavage site mapping in multiple cell types\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological criteria distinguish activities, single lab\",\n      \"pmids\": [\"11278735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IFN-γ produced by activated T cells inhibits RANKL-induced osteoclastogenesis by inducing rapid degradation of the RANK adapter protein TRAF6, thereby blocking NF-κB and JNK activation downstream of RANK. Separately, RANKL itself induces IFN-β (but not IFN-α) in osteoclast precursors, and IFN-β in turn inhibits osteoclast differentiation by interfering with RANKL-induced c-Fos expression—establishing a negative feedback loop.\",\n      \"method\": \"In vitro osteoclastogenesis, Western blot for TRAF6 degradation, NF-κB/JNK activation assays, IFN-β gene induction assay, c-Fos expression analysis\",\n      \"journal\": \"Arthritis research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two distinct mechanistic pathways identified with direct biochemical measurements, in vivo validation mentioned\",\n      \"pmids\": [\"12110142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MMP-7 produced by osteoclasts at the tumor-bone interface processes membrane-bound RANKL to a soluble form that promotes osteoclast activation and tumor-induced osteolysis. MMP-7-deficient mice demonstrate reduced prostate tumor-induced osteolysis and RANKL processing, establishing MMP-7 as a sheddase for RANKL in pathological bone resorption.\",\n      \"method\": \"Microarray, in vitro MMP-7 cleavage of RANKL, MMP-7 knockout mice, in vivo tumor-bone model, osteolysis measurement\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic cleavage plus genetic (KO) in vivo validation, >270 citations\",\n      \"pmids\": [\"15894268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RANKL triggers migration of RANK-expressing human epithelial cancer cells and melanoma cells; in vivo neutralization of RANKL by OPG in a mouse melanoma metastasis model provides complete protection from paralysis and marked reduction in bone tumor burden but not in other organs, establishing RANKL as a directional migration cue for RANK+ cancer cells mediating tissue-specific bone metastasis.\",\n      \"method\": \"In vitro migration assay with recombinant RANKL, in vivo mouse melanoma metastasis model with OPG neutralization, tumor burden measurement\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro functional assay + in vivo pharmacological neutralization with organ-specific readout, >600 citations\",\n      \"pmids\": [\"16572175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Wnt signaling in osteoblasts transcriptionally represses RANKL (TNFSF11) gene expression through a β-catenin-dependent mechanism; overexpression of full-length but not transcriptionally inactive β-catenin inhibits RANKL promoter activity. Activation of Wnt signaling (LiCl or Wnt3a) in osteoblast-spleen cell co-cultures inhibits osteoclast formation without directly affecting osteoclast differentiation, survival, or activity in the absence of osteoblasts.\",\n      \"method\": \"Wnt3a and LiCl treatment of osteoblast/spleen cell co-cultures, β-catenin overexpression, RANKL promoter reporter assay, RANKL mRNA/protein measurement\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter assay plus functional co-culture assay, replicated concept\",\n      \"pmids\": [\"16522681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss-of-function mutations in the RANKL-encoding TNFSF11 gene cause autosomal recessive osteoclast-poor osteopetrosis in humans. Affected individuals lack osteoclasts in bone biopsies and cannot be cured by hematopoietic stem cell transplantation (confirming osteoclast precursors are not the primary defect), but exogenous RANKL induces functional osteoclast formation from their monocytes, demonstrating that RANKL is absolutely required for osteoclast differentiation in humans.\",\n      \"method\": \"Human genetics (mutation identification), bone biopsy histology, HSC transplantation outcome, exogenous RANKL rescue experiment on patient monocytes\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetic loss-of-function with direct ex vivo rescue experiment\",\n      \"pmids\": [\"17632511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RANK signaling in mammary carcinoma cells is required for pulmonary metastasis in Erbb2-transformed carcinoma; the major pro-metastatic RANKL source is tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells located adjacent to stromal cells. Exogenous RANKL stimulates pulmonary metastasis of RANK+ human breast cancer cells, and this dependence on T cells is replaceable by exogenous RANKL.\",\n      \"method\": \"In vivo mouse mammary tumor model, T cell depletion, exogenous RANKL administration, CD4+CD25+FOXP3+ T cell identification by flow cytometry and IHC\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vivo genetic and pharmacological approaches, >500 citations\",\n      \"pmids\": [\"21326202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RANKL is the paracrine mediator of progestin-induced mammary epithelial proliferation and a direct contributor to mammary tumorigenesis. MMTV-RANK transgenic mice show accelerated pre-neoplasias and increased mammary tumors after multiparity or hormone/carcinogen treatment, while pharmacological RANKL inhibition attenuates mammary tumor development in multiple models by reducing hormone-induced mammary epithelial proliferation and cyclin D1 levels.\",\n      \"method\": \"MMTV-RANK transgenic mice, pharmacological RANKL inhibition, MMTV-neu spontaneous tumor model, in vivo tumor assessment, cyclin D1 measurement\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complementary gain- and loss-of-function in vivo approaches, >480 citations\",\n      \"pmids\": [\"20881963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Sclerostin produced by osteocytes dose-dependently upregulates RANKL mRNA and downregulates OPG mRNA in osteocyte-like cells, increasing osteoclastic resorption approximately 7-fold in co-cultures with splenocytes or PBMCs. This catabolic effect is abolished by OPG and sclerostin does not directly induce osteoclastogenesis from monocultures, establishing a RANKL-dependent mechanism by which osteocyte-derived sclerostin promotes bone resorption.\",\n      \"method\": \"Recombinant sclerostin treatment of osteocyte cultures, RANKL/OPG qPCR, co-culture osteoclastogenesis and resorption assay, OPG blocking\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dose-response, OPG rescue, monoculture controls, >380 citations\",\n      \"pmids\": [\"21991382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The human TNFSF11 locus contains a T cell control region (hTCCR) located between -170 and -220 kb upstream of the TSS that acts as a cell type-selective distal enhancer set for T cell-specific expression. ChIP-chip revealed histone acetylation enrichment and c-FOS recruitment to the hTCCR following TCR activation, and MEK1/2 signaling is required for RANKL induction in T cells. Both the RLD5a/b enhancer and hTCCR segments drove inducible reporter activity upon TCR stimulation.\",\n      \"method\": \"ChIP-chip, luciferase reporter assays, MEK1/2 inhibition (U0126), primary human T cells and Jurkat cells\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-chip plus functional reporter assays in primary cells, single lab\",\n      \"pmids\": [\"25211367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Deletion of the distal Tnfsf11 RL-D2 enhancer (23 kb upstream of TSS) in mice significantly blunts PTH-induced RANKL expression in vivo, reduces skeletal RANKL expression, decreases osteoclast numbers, and produces a progressive high bone mass phenotype. Ex vivo, RL-D2-/- stromal cells show decreased RANKL induction by forskolin and 1,25(OH)2D3. CREB binding at RL-D2 is induced by PTH/cAMP signaling.\",\n      \"method\": \"ChIP-seq, enhancer deletion in mice, in vivo PTH challenge, ex vivo stromal cell culture, bone phenotyping by microCT\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo enhancer deletion with multiple physiological readouts and ex vivo validation\",\n      \"pmids\": [\"26332516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Genetic inactivation of RANK in mammary epithelium or long-term pharmacological RANKL inhibition markedly delays onset, reduces incidence, and attenuates Brca1;p53 mutation-driven mammary cancer in mice. RANKL/RANK blockade impairs proliferation of murine Brca1;p53 mutant mammary stem cells and progenitors from human BRCA1 mutation carriers, placing RANKL-RANK signaling upstream of progenitor expansion in BRCA1-associated breast cancer.\",\n      \"method\": \"Conditional RANK knockout in mammary epithelium, pharmacological RANKL blockade, mammary stem cell and progenitor proliferation assays, human BRCA1-carrier tissue ex vivo\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two mouse models plus human tissue validation with mechanistic proliferation readout\",\n      \"pmids\": [\"27241552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LOX does not substitute for RANKL in osteoclastogenesis. LOX fails to generate TRAP+ osteoclasts or resorption pits from RANKL-deficient or RANK-deficient cells; in wild-type cells, LOX synergizes with RANKL only by stimulating RANKL expression in bone marrow stromal cells via ROS production. LOX injection does not rescue the RANKL-deficient osteopetrotic phenotype in vivo.\",\n      \"method\": \"RANKL/RANK-deficient mouse cells, LOX treatment, TRAP staining, resorption pit assay, in vivo LOX injection into RANKL-KO mice, ROS measurement\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic null backgrounds plus in vivo rescue experiment, definitive negative evidence\",\n      \"pmids\": [\"27606829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TRAF6 E3 ligase activity is not absolutely required for RANKL-induced osteoclastogenesis; RANKL-induced signaling in macrophages and bone marrow-to-osteoclast differentiation is normal in knockin mice expressing E3 ligase-inactive TRAF6[L74H], explaining the normal bone structure and teeth in these mice (unlike TRAF6 KO mice). This reveals that essential roles of TRAF6 in RANKL signaling are independent of its E3 ubiquitin ligase activity.\",\n      \"method\": \"TRAF6 E3 ligase-inactive knockin mice, osteoclastogenesis assay, bone phenotyping, macrophage RANKL signaling assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockin mouse genetic epistasis with in vitro and in vivo bone phenotype\",\n      \"pmids\": [\"28404732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RANKL-stimulated osteoclasts do not exclusively undergo apoptosis after resorption; by intravital imaging, RANKL-stimulated osteoclasts undergo fission into daughter cells called osteomorphs. Inhibiting RANKL blocks this cellular recycling and causes osteomorph accumulation, establishing RANKL as a regulator of osteoclast recycling/fission in addition to differentiation.\",\n      \"method\": \"Intravital imaging, RANKL inhibition, single-cell RNA sequencing, genetic deletion of osteomorph-specific genes in mice\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct live imaging with pharmacological and genetic validation\",\n      \"pmids\": [\"33636130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A druggable binding site on soluble RANKL (distinct from the membrane RANKL-RANK interface) was identified by molecular dynamics simulations; small molecule S3-15 selectively inhibits soluble RANKL-RANK interaction without interfering with membrane RANKL-RANK interaction, demonstrating conformational/functional differences between soluble and membrane-bound RANKL forms. S3-15 shows anti-osteoporotic effects in vivo without immunosuppression.\",\n      \"method\": \"Molecular dynamics simulation, in vitro binding assay (KD measurement), cell-based osteoclastogenesis assay, in vivo osteoporosis model, in silico and in vitro binding model validation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — computational plus in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"36097003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In situ hybridization across species and skeletal sites reveals that under physiological conditions RANKL (Tnfsf11) is expressed mainly by osteoprogenitor bone surface cells proximate to osteoclasts, while OPG is expressed mainly by osteocytes and bone-forming osteoblasts. OPG:Fc treatment increases RANKL mRNA in trabecular bone surface cells and decreases OPG in bone surface cells/osteocytes, creating localized osteoclastogenic activation sites—explaining the denosumab rebound effect mechanistically.\",\n      \"method\": \"In situ hybridization across species and skeletal sites, OPG:Fc and PTH treatment of mice, single-cell RNA sequencing (public data reanalysis), co-expression analysis (Mmp13/Tnfsf11)\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct ISH localization with pharmacological perturbation, single lab but multi-species\",\n      \"pmids\": [\"39424806\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFSF11 (RANKL) is a TNF-family type II transmembrane protein expressed on osteoblasts, osteocytes, stromal cells, activated T cells, and regulatory T cells; it exists in membrane-bound and proteolytically shed soluble forms (cleaved by TACE/ADAM17 and MMP-7 among others), signals through its receptor RANK via a complex involving TRAF6 and c-Src to activate NF-κB, JNK, Akt/PKB, p38 MAPK, and NFATc1, and is the essential and non-substitutable cytokine for osteoclast differentiation, activation, survival, and recycling (via osteomorph fission), while also regulating dendritic cell survival, lymph node organogenesis, mammary gland lobuloalveolar development and tumorigenesis, cancer cell migration to bone, and central thermoregulation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNFSF11 (RANKL) is the master cytokine governing osteoclast biology and contributes to lymph-node organogenesis, mammary gland development, and hormone-driven tumorigenesis. Expressed primarily by bone surface osteoprogenitors and regulated through distal enhancers (RL-D2, hTCCR) responsive to PTH/cAMP, vitamin D3, glucocorticoids, and TCR signaling, RANKL functions as a homotrimeric TNF-family ligand that binds RANK on osteoclast precursors to drive differentiation via TRAF6, NF-κB, c-Fos, and NFATc1, while also directly activating mature osteoclasts through rapid actin-ring formation and promoting osteoclast survival by NF-κB–dependent suppression of Fas-mediated apoptosis [PMID:9950424, PMID:10225954, PMID:9600092, PMID:15619676, PMID:26332516]. Beyond bone, RANKL/RANK signaling is required for lymph-node formation and lymphocyte development, expands mammary progenitors to promote BRCA1-mutation–driven breast tumorigenesis, drives osteosarcoma progression through osteoclast hyperactivity, and stimulates uterine leiomyoma proliferation via cyclin D1 induction [PMID:9950424, PMID:27241552, PMID:26659571, PMID:29741640]. OPG serves as an endogenous soluble decoy receptor that competitively blocks RANKL–RANK interaction, and RANKL-stimulated osteoclasts can undergo fission into transcriptionally distinct daughter cells (osteomorphs) as an alternative fate to apoptosis [PMID:9600092, PMID:33636130].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing that RANKL is sufficient to induce human osteoclast differentiation from monocytes without stromal support, and that OPG is its endogenous inhibitor, defined RANKL as the long-sought osteoclastogenic cytokine.\",\n      \"evidence\": \"Human PBMC culture with recombinant soluble RANKL and M-CSF; TRAP staining, resorption pit assay, OPG inhibition\",\n      \"pmids\": [\"9600092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity (RANK) not yet confirmed in this study\", \"In vivo requirement not yet demonstrated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Genetic ablation of RANKL proved it is indispensable for osteoclastogenesis in vivo and unexpectedly revealed essential roles in lymph-node organogenesis and lymphocyte development, broadening RANKL biology beyond bone.\",\n      \"evidence\": \"RANKL-knockout mice with osteopetrosis, absent osteoclasts, absent lymph nodes, and lymphocyte defects\",\n      \"pmids\": [\"9950424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of lymph-node organogenesis role not dissected\", \"Relative contribution of membrane-bound versus soluble RANKL not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstration that RANKL directly activates mature osteoclasts via rapid actin-ring formation (within 30 minutes) and stimulates bone resorption established a function distinct from its role in precursor differentiation.\",\n      \"evidence\": \"Primary rat osteoclasts on bone slices, scanning electron microscopy, OPG blocking\",\n      \"pmids\": [\"10225954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling cascade for actin ring induction not mapped\", \"Whether activation requires membrane-bound or soluble RANKL not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Characterization of the RANKL promoter identified vitamin D3 and glucocorticoid response elements and Cbfa1 binding sites, providing the first transcriptional framework for how hormonal signals regulate RANKL expression in osteoblasts.\",\n      \"evidence\": \"Promoter cloning, reporter assays, CpG methylation analysis in stromal cells\",\n      \"pmids\": [\"10209265\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Distal enhancers not yet identified\", \"In vivo relevance of identified elements not tested\", \"Contribution of individual elements not dissected by mutation in vivo\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The crystal structure of RANKL as a homotrimer with four unique surface loops explained receptor specificity and provided a structural basis for therapeutic targeting.\",\n      \"evidence\": \"X-ray crystallography at 2.6 Å with site-directed mutagenesis validated by osteoclastogenesis assay\",\n      \"pmids\": [\"11581298\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RANKL–RANK co-crystal structure not solved in this study\", \"OPG binding interface not mapped\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of at least two metalloprotease-dependent ectodomain shedding pathways distinct from TACE revealed how membrane-bound RANKL generates soluble forms with potential paracrine activity.\",\n      \"evidence\": \"Biochemical shedding characterization with TIMP sensitivity, stimulator pharmacology in multiple cell types\",\n      \"pmids\": [\"11278735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific sheddases not determined\", \"Relative biological potency of membrane-bound versus shed RANKL in vivo not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery that IFN-γ degrades TRAF6 and that RANKL-induced IFN-β suppresses c-Fos revealed negative-feedback and immune-crosstalk circuits that restrain osteoclastogenesis downstream of RANKL.\",\n      \"evidence\": \"TRAF6 degradation assays, NF-κB/JNK activation readouts, IFN-deficient mice\",\n      \"pmids\": [\"12110142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin-proteasome pathway for TRAF6 degradation not fully characterized\", \"Physiological significance of RANKL-induced IFN-β in vivo not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showing that PTH's osteoclastogenic effect operates through differentiation-stage-dependent regulation of both RANKL upregulation and OPG suppression in osteoblasts clarified how systemic hormones tune the RANKL/OPG axis.\",\n      \"evidence\": \"qRT-PCR time-course in differentiating primary mouse stromal cells with co-culture osteoclastogenesis\",\n      \"pmids\": [\"14969393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enhancer elements mediating PTH-responsive RANKL induction not yet identified\", \"In vivo cell-type resolution of PTH response not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrating that RANKL acts as an osteoclast survival factor by suppressing Fas expression through NF-κB established a third functional axis—survival—beyond differentiation and activation.\",\n      \"evidence\": \"Fas promoter reporter, EMSA, caspase-3 assay, dose-dependent Fas downregulation in mature osteoclasts\",\n      \"pmids\": [\"15619676\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this survival mechanism operates independently of other anti-apoptotic pathways not resolved\", \"In vivo confirmation using Fas-deficient osteoclasts not performed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of TRPV2 as a RANKL-induced calcium channel required for Ca²⁺ oscillations and NFATc1 nuclear translocation connected RANKL signaling to calcium-dependent transcriptional activation.\",\n      \"evidence\": \"siRNA knockdown, patch clamp electrophysiology, live-cell calcium imaging in RAW264.7\",\n      \"pmids\": [\"20980052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of other calcium channels (e.g., TRPV4, Orai1) not excluded\", \"In vivo validation of TRPV2 requirement not performed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placing PKCβ upstream of GSK-3β inactivation and NFATc1 induction, and miR-26a as a RANKL-induced negative regulator targeting CTGF/DC-STAMP, added kinase and post-transcriptional layers to the RANKL-NFATc1 axis.\",\n      \"evidence\": \"PKCβ inhibitor/RNAi with in vivo calvarial bone model; miR-26a mimic/inhibitor with CTGF rescue\",\n      \"pmids\": [\"25256217\", \"25518928\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PKCβ phosphorylation of GSK-3β not shown biochemically\", \"miR-26a findings from single lab, not independently replicated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of distal enhancers (RL-D2 for bone/PTH, hTCCR for T cells) controlling RANKL expression in a cell-type–specific manner resolved how a single gene is regulated in diverse tissues by different stimuli.\",\n      \"evidence\": \"In vivo enhancer deletion (RL-D2) producing high bone mass; ChIP-chip/reporter assays for hTCCR in T cells\",\n      \"pmids\": [\"26332516\", \"25211367\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Complete enhancer repertoire not mapped\", \"How distal enhancers physically contact the promoter (3D chromatin architecture) not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that FOXO1 mediates RANKL-induced osteoclastogenesis by regulating NFATc1 nuclear localization and downstream effectors added a forkhead transcription factor node to the RANKL signaling cascade.\",\n      \"evidence\": \"Conditional LyzM-Cre FOXO1 knockout mice, siRNA in RAW264.7, NFATc1 localization analysis\",\n      \"pmids\": [\"25694609\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FOXO1 is directly phosphorylated by RANKL-activated kinases not determined\", \"Relationship between FOXO1 and other RANKL-induced transcription factors (c-Fos, MafB) not integrated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Whole-body RANKL deletion abrogated osteosarcoma tumorigenesis in genetically engineered mice, establishing RANKL as a non-cell-autonomous driver of bone cancer through osteoclast-mediated tumor microenvironment remodeling.\",\n      \"evidence\": \"Conditional and whole-body Rankl KO in Rb/p53/Prkar1α-deleted osteosarcoma models; RANK-Fc pharmacological treatment\",\n      \"pmids\": [\"26659571\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RANKL acts solely through osteoclasts or also directly on tumor cells not fully resolved\", \"Human clinical relevance not yet confirmed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that RANK deletion in mammary epithelium delays BRCA1-mutation–driven breast cancer and that RANKL blockade suppresses mammary progenitor expansion established RANKL as a paracrine oncogenic signal in hormone-driven breast tumorigenesis.\",\n      \"evidence\": \"Mammary-specific Rank conditional KO, pharmacological RANKL inhibition, human BRCA1 carrier progenitor assays\",\n      \"pmids\": [\"27241552\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors in mammary progenitors not fully mapped\", \"Whether RANKL inhibition provides clinical cancer prevention benefit in BRCA1 carriers is untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The finding that TRAF6 E3 ligase activity is dispensable for RANKL-induced osteoclastogenesis in vivo overturned the assumption that TRAF6 ubiquitin ligase function is the primary effector mechanism in RANK signaling.\",\n      \"evidence\": \"TRAF6[L74H] E3 ligase-inactive knockin mice with normal osteoclast differentiation and bone structure\",\n      \"pmids\": [\"28404732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which TRAF6 function (scaffolding? other) mediates RANKL signaling remains undefined\", \"Whether E3 activity contributes under stress or pathological conditions not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that RANKL-stimulated osteoclasts undergo fission into transcriptionally distinct osteomorphs revealed a previously unknown recycling cell fate alternative to apoptosis, redefining the osteoclast lifecycle.\",\n      \"evidence\": \"Intravital imaging, scRNA-seq, RANKL inhibition causing osteomorph accumulation\",\n      \"pmids\": [\"33636130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals controlling fission versus apoptosis fate decision not identified\", \"Functional significance of osteomorphs in bone homeostasis not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genome-wide mapping of RANKL-induced superenhancer remodeling, with BATF1/3 as key transcription factors and SE-eRNAs regulating NFATc1, provided an epigenomic framework for how RANKL reprograms macrophage identity toward osteoclasts.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, PRO-seq, nuclear RNA-seq, siRNA knockdown of BATF and SE-eRNAs\",\n      \"pmids\": [\"36513810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether superenhancer formation is reversible upon RANKL withdrawal not tested\", \"Relationship between SE remodeling and osteomorph transcriptional identity not explored\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"In situ hybridization resolved that bone surface osteoprogenitors (not osteocytes) are the primary RANKL-expressing cells driving trabecular osteoclastogenesis, and that OPG blockade paradoxically increases RANKL at these sites, offering a mechanistic explanation for denosumab rebound.\",\n      \"evidence\": \"Multi-species in situ hybridization, OPG:Fc treatment of mice, scRNA-seq validation\",\n      \"pmids\": [\"39424806\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether osteocyte-derived RANKL is important in cortical bone not addressed\", \"Mechanism of RANKL upregulation upon OPG blockade not determined\", \"Single study requiring independent confirmation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of RANKL sheddases, the precise TRAF6-independent signaling mechanism downstream of RANK, the signals governing osteoclast fission versus apoptosis fate decisions, and the functional role of osteomorphs in bone homeostasis.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Sheddase identity remains unknown\", \"TRAF6 E3-independent RANK signaling mechanism undefined\", \"Osteomorph function in vivo not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4, 24]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 6, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 12]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 13, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFRSF11A\",\n      \"TNFRSF11B\",\n      \"TRAF6\",\n      \"NFATC1\",\n      \"FOS\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"TNFSF11 (RANKL) is a type II transmembrane TNF-family cytokine that functions as the essential, non-substitutable ligand for RANK-mediated osteoclast differentiation, activation, survival, and recycling, while also regulating dendritic cell survival, lymph node organogenesis, and mammary epithelial proliferation [PMID:9520411, PMID:9950424, PMID:33636130, PMID:20881963]. Expressed predominantly by osteoblast-lineage cells, osteocytes, and activated T cells under the control of distal enhancers responsive to PTH/cAMP, vitamin D3, and TCR signaling, RANKL exists in membrane-bound and soluble forms generated by proteolytic shedding via TACE and MMP-7 [PMID:10224132, PMID:15894268, PMID:26332516, PMID:25211367]. Upon binding RANK, it assembles a signaling complex involving TRAF6 and c-Src that activates NF-κB, JNK, Akt/PKB, and NFATc1 to drive osteoclast gene programs, with IFN-β–mediated negative feedback restraining differentiation [PMID:10635328, PMID:12110142]. Loss-of-function mutations in human TNFSF11 cause autosomal recessive osteopetrosis characterized by absent osteoclasts, and RANKL–RANK signaling in RANK-expressing cancer cells promotes bone-tropic metastasis and BRCA1-mutation-driven mammary tumorigenesis [PMID:17632511, PMID:16572175, PMID:27241552].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Cloning of RANKL as a T-cell-expressed TNF-family ligand that activates JNK and regulates dendritic cell survival established the gene's identity and first biological functions outside bone.\",\n      \"evidence\": \"Expression cloning from activated T cells, JNK kinase assays, DC survival assays with dominant-negative TRAF2 transgenic mice\",\n      \"pmids\": [\"9312132\", \"9367155\", \"9396779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Role in bone metabolism not yet recognized\",\n        \"Receptor on osteoclast lineage not identified\",\n        \"In vivo relevance to immune or skeletal homeostasis untested\"\n      ]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of RANKL as the osteoblast/stromal-cell-derived osteoclast differentiation factor (ODF/OPGL) resolved the longstanding question of how osteoblasts communicate with osteoclast precursors, showing that RANKL alone replaces stromal cells, vitamin D3, and glucocorticoids for osteoclastogenesis and causes hypercalcemia in vivo.\",\n      \"evidence\": \"Expression cloning from stromal cDNA library, reconstituted osteoclastogenesis without stromal cells, OPG blocking, in vivo mouse injection\",\n      \"pmids\": [\"9520411\", \"9568710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether RANKL is truly non-redundant in vivo required genetic proof\",\n        \"Downstream signaling cascade from RANK uncharacterized\",\n        \"Proteolytic processing and soluble form significance unknown\"\n      ]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"RANKL-knockout mice demonstrated absolute in vivo requirement for RANKL in osteoclast formation, tooth eruption, and lymph node organogenesis, while parallel biochemical studies delineated the RANK–TRAF6–c-Src–Akt signaling axis and identified TACE-mediated ectodomain shedding.\",\n      \"evidence\": \"RANKL-null mice (skeletal/immune phenotyping), co-IP and kinase assays in c-Src-deficient cells, in vitro TACE cleavage with N-terminal sequencing, osteoclast actin ring and resorption assays on bone slices\",\n      \"pmids\": [\"9950424\", \"10635328\", \"10224132\", \"10225954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of RANKL-RANK specificity unknown\",\n        \"Whether additional sheddases exist beyond TACE\",\n        \"Negative feedback mechanisms limiting osteoclastogenesis undefined\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The crystal structure of the RANKL trimer revealed unique surface loops that determine RANK-binding specificity, while additional sheddase activities distinct from TACE were shown to operate in different cell types, complicating the picture of soluble RANKL generation.\",\n      \"evidence\": \"X-ray crystallography at 2.6 Å with mutagenesis-coupled osteoclastogenesis, metalloprotease inhibitor profiling in multiple cell types\",\n      \"pmids\": [\"11581298\", \"11278735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Co-crystal structure of RANKL-RANK complex not yet solved\",\n        \"Identity of non-TACE sheddases not determined\",\n        \"Relative contributions of membrane-bound vs soluble RANKL to physiology unclear\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of IFN-γ-mediated TRAF6 degradation and RANKL-induced IFN-β negative feedback established that RANKL signaling is self-limiting, explaining how the immune and skeletal systems restrain osteoclastogenesis.\",\n      \"evidence\": \"In vitro osteoclastogenesis with Western blot for TRAF6 degradation, NF-κB/JNK and c-Fos expression analysis\",\n      \"pmids\": [\"12110142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Quantitative contribution of IFN-β feedback vs IFN-γ to in vivo bone homeostasis unclear\",\n        \"Whether other negative regulators act at the same nodes not resolved\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"MMP-7 was identified as a pathologically relevant RANKL sheddase at the tumor-bone interface, directly linking proteolytic release of soluble RANKL to tumor-induced osteolysis.\",\n      \"evidence\": \"MMP-7 knockout mice with prostate tumor-bone model, in vitro MMP-7 cleavage of RANKL\",\n      \"pmids\": [\"15894268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether MMP-7 cleaves RANKL at the same site as TACE not resolved\",\n        \"Relative contribution of MMP-7 vs other sheddases in non-tumor settings unknown\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"RANKL was shown to act as a chemotactic cue directing RANK-expressing cancer cells to bone, while Wnt/β-catenin signaling was found to repress RANKL transcription in osteoblasts—expanding RANKL's roles from differentiation factor to metastasis mediator and linking its expression to anabolic skeletal pathways.\",\n      \"evidence\": \"In vitro migration assay and in vivo melanoma metastasis model with OPG neutralization; β-catenin overexpression and Wnt3a/LiCl treatment of osteoblast co-cultures with RANKL promoter reporters\",\n      \"pmids\": [\"16572175\", \"16522681\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether RANKL is sufficient or merely permissive for bone metastasis tropism\",\n        \"Full catalog of transcription factors controlling cell-type-specific RANKL expression incomplete\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Human loss-of-function mutations in TNFSF11 were shown to cause autosomal recessive osteopetrosis, and patient monocytes formed osteoclasts when provided exogenous RANKL, proving RANKL is absolutely required for human osteoclastogenesis and that the defect lies in the microenvironment, not in precursor cells.\",\n      \"evidence\": \"Human genetic mutation identification, bone biopsy histology, failed HSC transplantation, ex vivo RANKL rescue of patient monocytes\",\n      \"pmids\": [\"17632511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether partial loss-of-function alleles produce milder human skeletal phenotypes unknown\",\n        \"Immune consequences (lymph node, DC) of human RANKL deficiency incompletely characterized\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"RANKL was established as the paracrine mediator of progestin-driven mammary epithelial proliferation and tumorigenesis, with regulatory T cells identified as a major RANKL source promoting pulmonary metastasis of mammary carcinoma.\",\n      \"evidence\": \"MMTV-RANK transgenic mice, pharmacological RANKL inhibition in mammary tumor models, Treg depletion and RANKL add-back in vivo\",\n      \"pmids\": [\"20881963\", \"21326202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether RANKL drives mammary tumorigenesis independent of progesterone in humans not established\",\n        \"Molecular mechanism of RANKL-induced mammary progenitor expansion vs differentiation unclear\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Dissection of distal enhancer elements (RL-D2) demonstrated how PTH/cAMP signaling controls RANKL expression in bone, while genetic RANK inactivation in mammary epithelium confirmed RANKL-RANK as a therapeutic target in BRCA1-associated breast cancer by restraining progenitor expansion.\",\n      \"evidence\": \"In vivo enhancer deletion in mice with PTH challenge and microCT; conditional RANK knockout and pharmacological RANKL blockade in Brca1;p53 mammary cancer models plus human BRCA1-carrier tissue\",\n      \"pmids\": [\"26332516\", \"27241552\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full enhancer landscape for RANKL in non-skeletal tissues (mammary, lymph node) not mapped\",\n        \"Clinical efficacy of RANKL inhibition for BRCA1-associated breast cancer prevention not yet demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The finding that TRAF6 E3 ubiquitin ligase activity is dispensable for RANKL-induced osteoclastogenesis revised the mechanistic model of RANK signaling, showing TRAF6 serves an essential scaffolding function independent of its catalytic activity.\",\n      \"evidence\": \"TRAF6 E3 ligase-inactive knockin mice with normal bone and osteoclastogenesis\",\n      \"pmids\": [\"28404732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Which TRAF6 domain mediates the E3-independent scaffolding for RANK signaling unknown\",\n        \"Whether other E3 ligases compensate at the RANK signalosome not investigated\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Intravital imaging revealed that RANKL-stimulated osteoclasts undergo fission into 'osteomorphs' rather than exclusively apoptosing, expanding RANKL's role from osteoclast formation to osteoclast lifecycle regulation and recycling.\",\n      \"evidence\": \"Intravital imaging of osteoclast fission, RANKL inhibition blocking recycling, scRNA-seq and genetic deletion of osteomorph-specific genes\",\n      \"pmids\": [\"33636130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Signals that determine osteoclast fission vs apoptosis downstream of RANKL not identified\",\n        \"Whether osteomorphs contribute to bone-remodeling coupling signals unknown\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of a druggable binding site unique to soluble RANKL demonstrated that membrane-bound and soluble RANKL have conformational differences exploitable for selective inhibition, achieving anti-osteoporotic effects without immunosuppression in vivo.\",\n      \"evidence\": \"Molecular dynamics simulation, KD measurement, cell-based osteoclastogenesis assay, in vivo osteoporosis model with small molecule S3-15\",\n      \"pmids\": [\"36097003\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Independent replication of selective soluble-RANKL inhibitor efficacy not yet reported\",\n        \"Structural validation of the proposed soluble-RANKL-specific binding pocket by co-crystallography absent\",\n        \"Long-term safety and specificity of soluble-RANKL-selective inhibition not characterized\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"High-resolution in situ hybridization across species resolved that osteoprogenitor cells at the bone surface—not mature osteoblasts or osteocytes—are the primary physiological RANKL source, and that OPG:Fc treatment paradoxically upregulates local RANKL, providing a mechanistic explanation for the denosumab rebound phenomenon.\",\n      \"evidence\": \"Multi-species in situ hybridization, OPG:Fc and PTH treatment of mice, scRNA-seq reanalysis\",\n      \"pmids\": [\"39424806\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether the osteoprogenitor RANKL source dominance holds in pathological states (inflammation, cancer) not tested\",\n        \"Molecular mechanism of OPG:Fc-induced RANKL upregulation not delineated\",\n        \"Findings from single lab with limited human tissue validation\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the precise signals distinguishing osteoclast fission from apoptosis downstream of RANKL, the full cis-regulatory architecture governing tissue-specific RANKL expression, the structural basis for soluble versus membrane-bound RANKL conformational differences, and whether selective soluble-RANKL inhibition can achieve clinical benefit in humans.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No co-crystal structure of RANKL–RANK complex at high resolution available\",\n        \"Enhancer landscape of RANKL in mammary and lymphoid tissues unmapped\",\n        \"Osteomorph biology and its regulation by RANKL poorly understood\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 9]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [9, 14, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 8, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 7]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 17, 19]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 26]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [15, 18, 19, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFRSF11A\",\n      \"TNFRSF11B\",\n      \"TRAF6\",\n      \"SRC\",\n      \"ADAM17\",\n      \"MMP7\",\n      \"CTNNB1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}